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Abstract 
 
Genomic aberrations are primary contributors to the pathophysiology of cancer [11]. 
Dysregulated expression of genes located within these aberrations are important predictors of 
chemoresistance, disease prognosis, and patient outcome [12]. This dissertation is focused on 
understanding the regulation and/or functions of specific genes located at dysregulated genomic 
regions such as 3q26 and 14q32 in the biology of ovarian and renal cancer, respectively.  
Serous epithelial ovarian cancer (EOC) manifest amplification at the 3q26.2 locus [2], an 
observation consistent with the cancer genome atlas (TCGA) [13]. The most amplified gene in 
this region is EVI1 which has been extensively studied in hematological malignancies [2]. 
However, its contribution to the pathophysiology of solid cancers remains unknown. We 
hypothesized that dysregulated EVI1 and SnoN/SkiL expression (located at the 3q26.2 
amplicon) leads to the altered cellular functional response, thereby contributing to the 
pathophysiology of ovarian cancer. Our group has previously shown that EVI1 splice forms may 
exhibit altered subcellular localization and functional properties relative to the wild type form 
[14]. In Chapter 3 of this dissertation, we identified that EVI1 splice forms could modulate 
epithelial-mesenchymal transition. Our findings indicate that siRNA construct targeting the splice 
junction between exon 2 of MDS1 to exon 2 of EVI1, (reduces the expression of MDS1/EVI1 
and EVI1Del190-515 splice forms) increases epithelial cell markers while decreasing mesenchymal 
markers and reducing migratory potential of ovarian and breast cancer cells.    
SnoN/SkiL, another gene overexpressed at the 3q26 is reported by our group to be 
induced upon As2O3 treatment in ovarian cancer cells via unknown mechanisms [15]. This 
induction of SnoN opposes the apoptotic cell death pathway induced by the drug treatment [15]. 
	xi 
	
We have previously identified that the PI3K/AKT pathway (also dysregulated in ovarian cancer 
[16]) contributes to the up-regulation of SnoN upon treatment with As2O3 [17]. However, SnoN is 
regulated via multiple mechanisms including post-translational modifications [18]. Additionally, 
c-Ski (a homolog of SnoN) is regulated post-transcriptionally by numerous miRNAs in cancer 
cells [19-22]. In Chapter 4, we attempted to identify potential miRNAs that could regulate SnoN 
expression post-transcriptionally. We discovered that miR-494 reduces both SnoN mRNA and 
protein levels. Our experimental outcomes also demonstrate that miR-494 further sensitizes 
ovarian cancer cells to drug treatment. 
Interestingly, miR-494 is located at the 14q32 region which has been shown to be down-
regulated in renal cancers [23]. Several reports indicate miR-494 to be involved in tumor 
suppressive responses including apoptosis and cell cycle arrest in various cancers [24-26]. 
However, its role in renal cancer biology remains unknown. We hypothesized that miR-494 
elicits a tumor suppressive response in renal cancer cells. Through our studies in Chapter 5, we 
demonstrate that miR-494 reduces cell viability and increases apoptotic response in renal 
cancer cells. We also show that miR-494 increases LC3B mRNA and protein levels. A 3’UTR 
luciferase assay indicated that LC3B may be a potential target of miR-494. Intracellular lipid 
droplets (LDs) increased in miR-494 expressing in a LC3B-dependent manner. This was 
accompanied with reduced intracellular cholesterol content, increased mitochondrial structural 
disorganization, and altered Drp1 localization.  
The outcome of our findings have improved our understanding of the regulation and 
functional response of these genes/miRNAs (EVI1, SnoN, and miR-494) in ovarian and renal 
cancers. The studies reported in Chapter 5 identified a novel function of miR-494 in increasing 
LDs and reducing renal cell survival. However, additional studies are warranted to fully 
understand the underlying mechanism of increased LDs formation in miR-494 expressing cells 
and the implication of miR-494 and other miRNAs at the 14q32 region in renal cancer biology. In 
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future, these studies will aid in the development of better treatment strategies which will 
contribute towards the management of cancer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	1 
	
 
 
 
 
Chapter 1  
 
Introduction 
  
Ovarian Cancer  
According to the American Cancer Society, ovarian cancer is the fifth most common 
cause of deaths due to cancer in women 
(http://www.cancer.org/cancer/ovariancancer/detailedguide/ovarian-cancer-key-statistics). The 
National Cancer Institute (NCI) predicts an estimated 21,290 new cases and 14,180 deaths in 
2015, due to ovarian cancer (http://seer.cancer.gov/statfacts/html/ovary.html). The high mortality 
rate of ovarian cancer is attributed to the lack of early stage detection methods [27]. Ovarian 
cancer is a heterogenous disease that can be classified into three major subtypes: (1) clear cell, 
(2) endometrioid, and (3) high grade serous [28]. The latter is the most common, accounting for 
~70% of the cases, whereas endometrioid and clear cell account for a total of ~20% of the 
cases [29]. Rarer forms account for the remaining ~10%. The origin and pathogenesis of 
ovarian cancer is complex.    
Due to the asymptomatic nature of this disease, diagnosis of ovarian cancer remains a 
significant problem. Therefore, identification of better prognostic markers is needed for early 
detection of this deadly disease. A common treatment strategy for epithelial ovarian cancer 
(EOC) involves a combination of surgery, followed by treatment with taxanes and platinum-
based chemotherapeutic drugs [30]. Cisplatin is the most common first-line treatment regime, 
although patients develop resistance to the drug over time [31]. Other first-line treatment options 
include anti-angiogenic drugs such as bevacizumab [32] and pegylated liposomal doxorubicin 
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[33]. Recent reports have also shown PARP (poly (ADP-ribose) polymerase) inhibitors as 
promising therapeutic tools for the treatment of epithelial ovarian cancer [34]. However, after 
completion of primary therapy, the risk for recurrence is around 60-70% [35]. Therefore, 
improved treatment strategies are direly needed to better treat patients with ovarian cancer. 
 
Breast Cancer  
Breast cancer is the most common form of cancer among women in the United States 
and the second most common cause of cancer related mortality in women 
(http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-key-statistics). It is 
estimated that there will be 231,840 new cases and 40,290 deaths in 2015 due to this disease 
(http://seer.cancer.gov/statfacts/html/breast.html). Breast cancers can be classified into three 
broad categories based on HER2 and ER/PR status. These are (1) luminal A (ER and /or PR+, 
HER2 -), (2) luminal B (ER and /or PR+, HER2 +), (3) triple negative/basal-like (ER and /or PR-, 
HER2 -), and (4) HER2 type (ER and /or PR-, HER2 +) [36] [37] [38]. The luminal A cancers are 
the most prevalent (~40%), followed by luminal B (~20%), triple negative (~15-20%), and HER2 
(~10-15%) [37]. The treatment strategies for breast cancers include tyrosine kinase and 
angiogenic inhibitors [39]. Hormone therapy is the most favorable line of treatment for hormone 
positive breast cancers [40]. The use of taxanes with other chemotherapeutic drugs is an 
effective combinatorial strategy; however, there is a high incidence of toxic effects with this 
strategy [40]. Therefore, better treatment strategies are needed to combat breast cancer.   
    
Renal Cancer  
Renal cell carcinoma can be subdivided into various categories which are (1) clear cell, 
(2) papillary, (3) chromophobe, (4) oncocytic, and (5) collecting duct. The clear cell renal cancer 
is the most frequent subtype, which affects ~70% of patients with renal cancer. According to 
NCI, the estimated new cases and deaths from kidney (and renal pelvis) cancer in the USA in 
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2015 are 61,560 and 14,080, respectively (http://seer.cancer.gov/statfacts/html/kidrp.html).  
Renal cancer can be acquired in a sporadic or hereditary manner. The gene associated with the 
hereditary form of this cancer is von Hippel-Lindau (VHL), which is located at 3p25. Renal 
cancer is a metabolic disease and the VHL/HIF pathway dysregulation is crucial in renal cancer 
progression [41]. VHL deletion is also associated with sporadic forms of renal carcinoma [42] 
[43]. This protein is an E3 ubiquitin ligase and its primary function is in the regulation of the 
hypoxia response pathway, which is a metabolic pathway critical for tumor survival under 
hypoxic conditions [44]. Under normoxia, VHL ubiquitinates and targets HIF1α (hypoxia 
inducible factor 1 alpha) for degradation, thereby inhibiting the expression of HIF1α-regulated 
genes [45].  
The current treatment strategies for renal cancer can be grouped into four categories: (1) 
surgery, (2) radiation therapy, (3) immunotherapy, and (4) molecular-targeted therapy. The 
surgical and radiation approaches are dependent on the stage of the disease. 
Immunotherapeutic treatment may include IL-2 and IFN-α [46]. Targeted therapy involves  
kinase inhibitors of VEGF, PDGF, TGFβ, and mTOR, such as sunitinib, pazopanib, axitinib, 
sorafenib, tivozanib, and temsirolimus [46]. Identification of predictive biomarkers will aid in 
improving treatment outcomes. 
 
Genomic Aberrations   
Genetic instability is a hallmark of cancer and a major cause of genomic alterations 
involving DNA copy number changes and/or mutations [47]. Gain-of-function mutations or DNA 
copy number gains can activate proto-oncogenes. In a similar manner, loss-of-function 
mutations or DNA copy number losses can inactivate a tumor suppressor gene, thus disrupting 
normal gene functions [48]. The common genomic alterations associated with serous EOC 
include copy number gains at 1q, 3q, 7q, and 8q; whereas losses occur at 17p, 19q and 22q 
[13] [49]. The most common genes mutated in serous EOC include TP53, BRCA1, BRCA2 [50], 
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and additional PTEN mutations which are correlated with a worsened patient outcome [51].  
Mutations in BRCA1/2, TP53, PTEN, STK11, and CDH1 are associated with a high risk for 
development of breast cancers [52]. It is interesting that serous EOC and basal-like breast 
tumors exhibit similar molecular characteristics, suggesting that analogous therapeutic 
opportunities can be investigated for treatment [53]. The most common deletion in the 3p region 
in renal cancers involves mutations/deletions in four major genes: VHL, PBRM1, BAP1, and 
SETD2 [43]. The loss of 14q chromosomal region harboring HIF1is also a frequent event 
leading to an aggressive phenotype [23, 45]. There is also a gain at the 5q chromosomal region, 
which leads to an increase in SQSTM1, associated with development of renal cancer [43] [54].  
 
Chromosomal Aberrations at 3q: Serous EOC and BRCA1 Positive Basal Breast Cancers 
In particular, amplification of the 3q26 chromosomal region is an early and common 
event in epithelial cancers, including basal BRCA1 positive breast [55] [56] and serous EOC [2]. 
The genes that are amplified at this regions include catalytic subunit of phosphoinositide-3-
Figure 1: Human chromosome 3q 
 
The q arm of human chromosome 3 showing the genes that are amplified in several solid 
cancers [1, 2]. These include (1) EVI1, SnoN/SkiL, and PKC at 3q26.2, (2) PIK3CA at 3q26.3, 
(3) Claudin-1 at 3q28, and (4) PLSCR1 (Phospholipid scramblase 1) at 3q23. (Adapted from 
Dr. Nanjundan’s grant proposal). (*Figure created by Punashi Dutta)    
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kinase (PI3K) (PIK3CA), Protein Kinase C, Iota (PKC)EVI1 [2], and SnoN [1] (Figure 1). Our 
studies reported in Chapter 4 focus on the contribution of EVI1 and SnoN in ovarian and/or 
breast cancer biology. 
 
Ecotropic viral integration site-1 (EVI1) 
 
Gene structure: 
Transcripts of EVI1 are encoded by the MECOM (MDS1-EVI1 complex locus) locus [57]. 
As depicted in Figure 2, the EVI1 gene is composed of 16 exons [57] and is over 100 kb long 
[58]. The start and the stop codon for EVI1 are located at exon 3 and 16, respectively [59]. The 
EVI1 nuclear protein consists of 1051 amino acids and is ~145 kDa [58]. The EVI1 protein 
contains two Zinc (Zn) finger domains (7 and 3 Zn finger motifs, respectively from the N- to the 
C-terminal region) and an acidic C-terminal region [60].  The intervening region (IR) and 
Figure 2: EVI1 gene structure 
 
Schematic representation of EVI1 gene structure including exonic regions and important 
functional domains. The first Zinc (Zn) finger domain contains 7 Zn fingers, which is followed by 
the intervening region and the repressor domain. The second Zn finger domain, containing 3 Zn 
fingers follows the repressor domain. The EVI1 gene consists of 16 exons; the mRNA product of 
which translates into a protein with 1051 amino acids. (Adapted from Dr. Nanjundan’s grant 
proposal). (*Figure created by Punashi Dutta) 
	
	6 
	
repressor domain are located in between the two Zn finger domains. EVI1 has been shown to 
bind to the GATA2 promoter via its first Zn finger domain and enhance its transcription to control 
hematopoietic stem cell proliferation [61]. The first Zn finger domain is also required for the 
repression of the transforming growth factor beta 1 (TGF) pathway via interaction with Smad3 
[62]. EVI1 is known to interact with other Smad family members (i.e., Smad1, 2, and 4) [63]. 
EVI1 inhibits JNK via direct interaction [64], antagonizing stress induced apoptosis, and thus 
contributing to leukemogenesis. The first Zn finger domain is also required for transformation of 
Rat1 fibroblasts [65].   
 
Splice variants: 
The MDS1/EVI1 splice variant is generated by the splicing of the second exon of 
myelodysplastic syndrome 1 (MDS1) to the second exon of EVI1, as indicated in Figure 3. This  
splice variant of EVI1 has an additional 188 codons: 125 of these arising from the exon 1 and 2 
of MDS1 and 63 codons arising from the exon 2 and 3 of EVI1 [4]. MDS1/EVI1 exhibits a novel 
PR domain with 40% homology to the PR domain of the histone methyltransferase, PRDM2 [4, 
66].  
Another splice variant of EVI1 lacking 324 amino acids within exon 7 has been identified 
in human endometrial carcinoma cells [67, 68]. This variant contains the 6th  and 7th Zn finger 
motifs of the 1st Zn finger domain but lacks the intervening region and a portion of the repressor 
domain and is designated as EVI1s [3] or Del324 [67]. EVI1 ∆105, a variant of EVI1 identified in 
murine leukemia cells, lacks  the C-terminal 105 amino acids which are located in exon 15 [59]. 
On occasion, variants of EVI1 that contain an insertion of 9 amino acids in the repressor domain 
(exon 9) have been reported; it does not appear to alter the activity of EVI1, as reported thus far 
[59]. Six different 5’ alternative EVI1 mRNA transcripts have been reported; these appear to be 
the result of altered initiation transcription start sites within the first exonic region leading to the 
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different fragments of the first exon spliced to the exon 2 [69]. The detailed functional response 
of these different splice variants of EVI1 is presently unclear. 
 
Interacting partners: 
The intervening region (amino acids 239-514), located after the first Zn finger domain, is 
required for the repressor activity of EVI1; this was demonstrated using a splice variant of EVI1 
lacking this region which was unable to transform Rat1 fibroblasts [65]. The repressor activity of 
EVI1 is also dependent on the proline-rich repressor domain which is required for its interaction 
Figure 3: Mechanism of splicing and formation of the MDS1/EVI1 splice variant 
 
The MDS1/EVI1 splice variant arises due to a splicing event between the exon 2 of MDS1 and 
exon 2 of EVI1, giving rise to a novel PR domain and a resultant protein with 1239 amino acids 
[4]. (*Figure created by Punashi Dutta)   
	
	8 
	
with C-terminal binding protein1 (CtBP1) [70] and for inhibiting the TGF pathway. However, 
this proline-rich region does not directly interact with Smads [62]. GATA2 up-regulation and 
inhibition of TGF signaling by EVI1 are required for the hematopoietic development [71]. The 
C-terminus of EVI1 interacts with BRG1 (SWI/SNF ATPase subunit factor involved in chromatin 
remodeling) and stimulates E2F1 activity and proliferation [72]. The second Zn finger domain is 
required for the interaction with c-FOS and activating AP-1 transcription [73]. The 8th Zn finger 
motif of this domain binds to RUNX1 which facilitates its DNA binding activity [74]. EVI1 also 
exhibits “non-DNA binding” properties and can act as a scaffold protein mediating transcriptional 
repression/activation [75, 76].   
EVI1 interacts with HDACs histone deacetylase (HDACs) [77] and histone acetylase 
(HATs) such as CREB-binding protein (CBP) (at amino acids 283-514) and p300/CBP-
associated factor (P/CAF) (at amino acids 1-283) [78]. These HATs acetylate EVI1 and promote 
its localization to nuclear speckle domains [78]. In contrast, HDACs and CtBP1 promote EVI1 
localization to the nuclear compartment, which has a diffused pattern of expression [78]. 
Acetylation of EVI1 at lysine residue 564 is required for the transcriptional activation of GATA2 
[79]. Interestingly, HDAC inhibitors can only partially relieve EVI1-mediated repression of target 
genes, indicating that other chromosomal modifications are required for EVI1-mediated 
repression [75]. Consistent with this notion, it has been reported that histone 
methyltransferases, SUV39H1 and G9a, interact with the N-terminal region of EVI1 and 
contribute to its repressor property [75, 76]. In addition, EVI1 can also bind to DNMT3a/3b and 
repress the transcription of miR-124-3 [80]. EVI1 binds to the promoter of the stress responsive 
gene, SIRT1 and induces its transcription [81]. However, SIRT1 is also shown to deacetylate 
and degrade EVI1 [81]. Moreover, EVI1 can bind to PTEN and repress its expression via 
binding to polycomb group of proteins (PcG), thus modulating the AKT/mTOR pathway [82].  
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Functions: 
Two decades ago, EVI1 was reported to be increased at the mRNA levels up to 40-fold 
in ovarian cancers via an RNAse protection assay [83]. This was supported by a similar study 
conducted in 2006, demonstrating increased EVI1 expression in advanced stage ovarian 
cancers, relative to normal via the use of expression profiling microarray [84]. The DNA copy 
number of EVI1 was found to be elevated in 43% of ovarian cancers [84]. Both MDS1/EVI1 
have been shown to contribute to the pathophysiology of ovarian cancer [2]. Increase in EVI1 
transcript levels are associated with worsened patient outcome while increase in EVI1 DNA 
copy number and MDS1/EVI1 transcripts have been associated with good patient outcome [2]. 
Transient transfection of EVI1 and MDS1/EVI1 in both normal ovarian cells stimulates cell 
proliferation, migration and decreases TGF-mediated PAI-1 promoter activity [2]. There is 
evidence supporting that MDS1/EVI1 is an antagonist of EVI1 [85]; MDS1/EVI1 has also been 
reported to act cooperatively with EVI1 [86] [87]. However, the function of MDS1 is presently 
unclear [4]. A recent study by Bard-Chapeau and group identified 78 interacting partners of 
EVI1/EVI1 splice variants via SILAC-based quantitative proteomics approach, and was further 
validated some of these targets by yeast-2-hybrid and co-immunoprecipitation studies, 
identifying EVI1 as a modulator of transcription, recombination, and mitosis [88]. EVI1 has not 
been widely studied in solid cancers other than that of the ovary. However, EVI1 gene copy 
number has been shown to be increased in colon and colorectal cancers [89, 90]. 
 
Ski-related novel protein N/ Ski-like protein (SnoN/SkiL) 
SnoN/SkiL (Ski-related novel protein-1/Ski-like oncogene) belongs to the Ski family of 
proto-oncogenes. SnoN transcription is induced by the TGF signaling pathway [91]. It 
negatively regulates the TGF pathway by binding to both R-Smads (Smad2/3) and the co-
Smad (Smad4), thus inhibiting their DNA binding ability and blocking the transcription of TGF-
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regulated genes [92]. SnoN binds to a number of transcriptional regulators such as N-CoR [93], 
and members of the HDAC family [94], thus inhibiting the activity of Smads. This inhibitory role 
in the TGF signaling pathway is required for the transforming ability and proliferative potential 
of SnoN and its related oncoprotein, Ski [95] [96]. The role of SnoN as an oncogene or a tumor 
suppressor gene in cancer is complex and dependent on the cancer type [18]. SnoN positively 
regulates cell cycle arrest and senescence in ovarian epithelial cells and also leads to enhanced 
cellular proliferation in ovarian cancer cells [1]. SnoN expression has been reported to be 
elevated in a number of cancers, including melanoma [97], esophageal squamous cell 
carcinoma [98], colorectal carcinoma [99], leukemia [100], and estrogen receptor-positive breast 
carcinoma [96]. On the contrary, it has also been reported that knockdown of SnoN in lung and 
breast cancer cells does not alter the transforming ability of these cells [101]. SnoN can also 
increase PML transcription via direct binding, leading to the localization of SnoN to PML nuclear 
bodies and thus inducing premature senescence via stabilization of p53 [18]. Furthermore, 
knockdown of SnoN via shRNA constructs can promote EMT and invasion of breast cancer 
cells in vitro as well as enhance tumor metastasis in vivo [101] [102]. 
SnoN subcellular localization is primarily nuclear (in malignant cells); however, studies 
have also shown SnoN to be localized to the cytoplasm (in normal tissues) [103]. The regulation 
of function and expression of SnoN is altered via post translational modifications [18]. Several 
E3 ubiquitin ligases have been identified to ubiquitinate and degrade SnoN upon TGF 
treatment, such as Smurf2 [104] and APC/C [105]. SnoN is rapidly degraded when it becomes 
phosphorylated by TAK1, a kinase that is activated by TGF treatment [106]. Prior studies 
performed in our laboratory have shown that SnoN expression is induced upon As2O3 treatment 
in ovarian cancer cells, leading to induction of a beclin-1-independent autophagic response in 
these cells [15]. The PI3K pathway is involved in this process; however, the exact mechanism 
underlying this event remains to be investigated [17].  
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Chromosomal Aberrations at 14q: Renal Cancer 
Loss of the 14q chromosomal locus is observed in various cancer types including kidney 
[107] [23, 108] [109, 110], breast [111], colorectal [112] [113, 114] ovarian [115], and 
gastrointestinal [116]. Anomalies in miRNAs at 14q32 locus have also been studied in ovarian 
[117] and bladder [118] cancer. Loss of key genes within this region has been shown to 
contribute to disease pathophysiology; thus, understanding the precise role of these genes that 
are lost will aid in a better understanding of this disease. In renal cancer, the 14q deletion is 
associated with worsened patient outcome and increased cancer recurrence [23]. As described 
earlier, VHL is deleted at the 3p locus and HIF1 is deleted at the 14q region; these events 
contribute to renal cancer biology [45]. 
  
The DLK1-DIO3 cluster and microRNAs (miRNAs) 
The DLK1-DIO3 region harbors the largest miRNA cluster in the human genome. In 
particular, the 14q32 miRNA cluster, contains 54 non-coding miRNAs, some of which are 
dysregulated in specific cancer types [119]. miRNAs are key regulators of gene expression 
involved in a spectrum of cellular processes and signaling pathways that impact cellular fate. 
Some miRNAs in this region shown to be altered in renal cancer include miR-127, miR-323a, 
miR-369, miR-376c, miR-379, miR-382, miR-485, and miR-493 [119]. In a separate study 
conducted by Juan and group, 5 miRNAs down-regulated in clear cell renal cell carcinoma 
(ccRCC) were identified namely miR-136, miR-154, miR-337, miR-377, and miR-411 [120].   
miRNAs are small non-coding RNAs involved in a plethora of biological processes and 
modulate a number of cancer-related pathways, such as apoptosis, cell cycle control, 
proliferation, migration, and metabolism [121]. The first identified miRNA was lin-4 in C.elegans 
and was shown to modulate the development timing of the nematode via targeting lin-14  [122]. 
Since then miRNAs have been widely studied with respect to their mRNA targets and functional 
outcome in disease pathogenesis. The contribution of miRNAs to cancer development was first 
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identified by a study conducted more than a decade ago in chronic lymphocytic leukemia [123] 
[124]. miRNAs are transcribed by RNA polymerase II from exonic sequences or from introns of  
protein coding genes [121] (Figure 4). After transcription, these long primary RNA (pri-miRNA) 
are cleaved by RNase III enzyme, Drosha and its co-factor, DGCR8 to generate 60-100 small 
RNA hairpins (pre-miRNA), which are then transported out of the nucleus into the cytoplasm by 
the action of Ran–GTP and Exportin 5. Once in the cytoplasm, RNase III enzyme, DICER 
further trims the pre-miRNA to form 21-24 nucleotide duplex, facilitated by TRBP and PACT 
Figure 4: miRNA biogenesis and mode of action 
 
The figure depicts the mechanism of miRNA biogenesis. Following transcription in the nucleus, 
pri-miRNA is cleaved by nuclear enzyme Drosha giving rise to pre-miRNA. This pre-miRNA is 
exported into the cytoplasm via exportin and further cleaved by Dicer to generate mature 
miRNA. Ago2 then loads the guide strand to the RISC complex and reduces target mRNA 
expression by translational inhibition or mRNA degradation [7]. (*Figure created by Punashi 
Dutta) 
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proteins  [7]. This gives rise to the miRNA-miRNA* duplex wherein the miRNA is the antisense 
or guide strand and the miRNA* is the sense or passenger strand [125]. This miRNA duplex is 
then loaded to the RISC (RNA-inducing silencing complex) complex along with argonaute 2 
(Ago2) protein which is involved in the dissociation of the passenger strand leading to the 
activated RISC complex [126]. This active RISC complex then binds to the target mRNA and 
based on the complementarity match can either inhibit translation (imperfect match) or lead to 
deadenylation and degradation of target mRNA (perfect match) [127]. However, recent evidence 
indicates that miRNAs may also induce transcriptional activation [128, 129]. The miRNA-
mediated increase in gene expression depends on a number of factors such as (1) the context 
of the RNA sequence, (2) the presence or absence of RNP (ribonucleoprotein), and (3) cellular 
conditions [130]. 
 
miR-494: 
miR-494 is located within the DLK1-DIO3 cluster at the chromosomal locus, 
chr14:101029634-chr14:101029714 [131]. miR-494 elicits contrasting responses in tumor cells. 
For example it targets both anti- and pro-apoptotic proteins [132]; indeed miRNAs can function 
both as oncogenic miRNAs (oncomirs [133]) or tumor suppressors in different cellular settings. 
miR-494 has been reported to be reduced in ovarian tumors [134]. miR-494 induces 
senescence in lung cancer cells [135] and inhibits proliferation via targeting c-KIT and HOXA10 
expression in gastrointestinal [24] and oral cancer [136], respectively. miR-494 also suppresses 
cell growth in prostate cancer cells [137] and causes G2/M cell cycle arrest in 
cholangiocarcinoma cells [138]. miR-494 expression has also been reported to increase with 
treatment of chemotherapeutic drugs such as cinobufacin, used in gastric cancer cells [139]. 
miR-494 also suppresses invasion, migration, proliferation, and induces apoptosis in 
nasopharyngeal carcinoma [140]. The oncogenic functions of miR-494, in contrast include its  
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Table 1: List of miR-494 targets identified according to published reports	
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up-regulation in certain cancers such as colorectal [141] and non-small cell lung cancer [142]. In 
addition, miR-494 inhibits expression of PTEN, a tumor suppressor [143, 144]. In hepatocellular 
carcinoma, miR-494 is up-regulated and plays a critical role in tumor progression [145, 146]. A 
summary of miR-494 targets is presented in Table 1.  
The role of miR-494 (located within the 14q32 cluster) in clear cell renal carcinoma has 
not yet been investigated. Therefore, analysis of its expression and functional responses in 
normal and renal cancer cells may provide useful insight into understanding molecular 
mechanisms underlying renal cancer biology.  
 
Pathways that Alter the Hallmarks of Cancer  
 
Transforming growth factor beta (TGFβ) pathway 
The TGF pathway regulates multiple cellular processes, including differentiation, 
proliferation, and apoptosis; dysregulation of this pathway is reported in various cancer types 
[147]. The signaling cascade is initiated by the TGF ligand binding to the TGFβ type-II receptor 
(TGFRII), resulting in the heterodimerization of TGFRII and TGFβ type-I receptor (TGFRI) 
followed by the phosphorylation of the R-Smads (Smad2/3) [148]. Phosphorylated Smad2/3 
interact with Smad4, translocate to the nucleus, and activate the transcription of TGF-
responsive genes [148]. TGF signaling can be negatively regulated by EVI1, SnoN/SkiL, and 
Smad7 [147]. The cellular responses elicited by the TGF pathway are cell type specific and 
moreover, the pathway elicits both tumor suppressive and oncogenic functions [149]. Of 
interest, ovarian cancer is characterized by dysregulated TGF signaling as a result of  EVI1 
and SnoN which are TGF corepressors, as well as TGFRII [150]. These changes lead to 
resistance towards the growth inhibition by TGF TGF can also induce EMT and invasion in 
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borderline ovarian serous cancers and promote apoptosis in low-grade ovarian tumors, 
supporting its dual role [151]. 
 
Epithelial-mesenchymal transition (EMT) 
During development, cells frequently undergo epithelial-mesenchymal transition in 
addition to mesenchymal-epithelial transition (MET) [152] (Figure 5). These pathways are 
crucial for basic cellular processes including implantation, embryogenesis, organ development, 
Figure 5: Mechanism of EMT 
 
The multi-step process of EMT begins with dysplasia, a phenotype which confers abnormal 
morphology to epithelial cells. This is followed by disruption of cell-cell and cell-ECM 
(extracellular matrix) connections. These cells then infiltrate the bloodstream and undergo 
metastases to distant organs, following which they undergo MET (mesenchymal-epithelial 
transition) [6]. (Adapted from “The Biology of Cancer”, Garland Science 2007). (*Figure 
created by Punashi Dutta) 
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and tissue regeneration [6]. In addition, EMT plays an important role in cancer biology since this 
pathway allows cancer cells to disseminate into the bloodstream and implant/grow at secondary 
metastases sites. [153].  
The process of EMT is characterized by well-defined steps and involves specific markers 
that dictate the epithelial versus mesenchymal phenotype of cells. The epithelial phenotype is 
characterized by cell-cell connections, which are maintained by the tight junction proteins [154]. 
When cancer cells transition from an epithelial to mesenchymal morphology, the cell junctions 
disintegrate and the basement membrane degrades [152]. The primary epithelial marker, E-
Cadherin is replaced by N-Cadherin, a mesenchymal marker. These changes promote a 
mesenchymal phenotype as well as resistance to anoikis (a cell death pathway promoted by 
detachment from the extracellular matrix [155]); the acquisition of this cellular characteristic will 
promote cellular migration and invasion [152] [156]. Claudin-1 is a tight junction protein, 
important in maintaining cell-cell connections. Interestingly, claudin-1 is located at chromosome 
3q28, in close proximity to the frequently dysregulated 3q26 region. Our laboratory findings 
have shown that genes located at neighboring chromosomal regions may regulate each other 
[157]; for example, PLSCR1 (located at 3q23) is regulated by SnoN/SkiL (located at 3q26.2). It 
is presently unknown whether genes such as EVI1, located at 3q26 may regulate claudin-1. 
 
Programmed cell death (PCD) 
The imbalance between cell division and cell death is an important feature of cancer 
cells [158]. PCD is characterized by a defined and regulated set of cellular events [159]. The 
two major types of PCDs are apoptosis and autophagy. There exist other cell death 
mechanisms including necrosis, as well as other pathway such as necroptosis, pyroptosis, 
entosis, and ferroptosis [160] [161]. 
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Apoptosis: 
Apoptosis is characterized by cell shrinkage, nuclear fragmentation, followed by 
sequestration of intracellular components into apoptotic bodies, a process referred to as 
“budding” [162]. These cells are then phagocytozed by macrophages. Apoptosis occurs as a 
normal cellular process to maintain cellular homeostasis [162]; however, cancer cells evade 
apoptosis [163]. There are two major apoptotic pathways: intrinsic and extrinsic pathways. The 
extrinsic pathway is activated, for example, by the binding of the ligand Fas L to its cognate 
receptor; this results in the recruitment of FADD and procaspase-8, which form the death-
inducing signaling complex (DISC) [164]. Pro-caspase-8 is then activated leading to activation 
of the executioner caspase-3. The intrinsic pathway is triggered by DNA damage and is 
dependent on the release of cytochrome c from the mitochondria, which recruits Apaf-1 and pro-
caspase 9 to form the apoptosome [164]. The Bcl-2 family of proteins includes both anti- and 
pro-apoptotic members. The pro-apoptotic proteins such as Bax and Bak aid in the release of 
cytochrome c from the mitochondria [165]. However, the anti-apoptotic proteins such as Bcl-2 
and Bcl-xL antagonize apoptosis by inhibiting the release of cytochrome c from the mitochondria 
by directly binding Bax and/or Bak [166]. 
  
Autophagy:  
Autophagy refers to a process in which damaged organelles and proteins are recycled in 
double-membrane vesicles called autophagosomes to obtain energy during conditions of stress, 
including starvation [167]. The autophagy related genes (ATG) were identified in the yeast in 
1993 [168]; the molecular basis of autophagy is conserved among yeast, plants, and mammals 
[169]. Autophagy can be divided into the following stages: (1) induction, (2) nucleation, (3) 
elongation and completion, (4) docking and fusion, and (5) degradation and recycling [170]. A 
schematic representation of this process including the proteins involved is depicted in Figure 6. 
Autophagy can be induced by a number of stimuli such as nutrient deprivation, stress, and 
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inhibition of mTORC1 (mammalian target of rapamycin) [5]. In all of these events, ULK1/ATG1 
becomes phosphorylated by AMPK [171]. mTORC1 (GL, mTOR, Raptor) is regulated by 
signaling pathways such as AMPK, PI3K/AKT, and MAPK [8]. Following induction, vesicle 
Figure 6: Schematic model of the autophagy pathway 
 
The induction of autophagy can be regulated via several mediators, for example active mTOR 
inhibits autophagy [5]. mTOR itself is regulated via various signaling pathways [8]. Bcl-2 inhibits 
autophagy by binding beclin-1 [9] and inhibiting the formation of the initiation complex. The 
autophagy pathway progress via two ubiquitin-like conjugation steps that involve the conjugation 
of ATG12 and ATG5 via ATG7 and ATG10 [10]. In the second step, ATG4 cleaves LC3 
exposing the cysteine residue where PE attaches via activation of ATG7 and ATG3. The 
conjugated ATG5-ATG12 act as the E3 ubiquitin ligase for this reaction. This lipidated form of 
LC3 (LC3-II) is bound to the autophagosome membrane. Following this, the autophagosome 
fuses with the lysosome leading to degradation of the damaged cellular components [10]. 
(Adapted from http://www.cellsignal.com/). (*Figure created by Punashi Dutta). 
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nucleation or formation of the phagophore membrane occurs, which is dependent on the 
complex formation between hVps34 or PI3KCIII, Vps15, and beclin-1 (pre-initiation complex) 
[172]. The vesicle elongation step is facilitated by two ubiquitin-like proteins involved in two 
ubiquitin-like pathways. The first ubiquitin-like pathway involves the conjugation of ATG12 to 
ATG5 via the E1-like protein, ATG7, and the E2-like protein, ATG10 [173, 174]. In the second 
ubiquitin-like pathway, ATG4 cleaves LC3, following which the E1 (ATG7) and E2 (ATG3)-like 
proteins conjugate PE (phosphatidylethanolamine) to LC3-I, leading to the formation of LC3-II 
[175, 176]. The conjugated ATG5-ATG12 act as the E3 ubiquitin ligase for this reaction. This 
lipidated form of LC3 (LC3-II) is then recruited to the autophagosomal membrane. When the 
autophagosome is fully formed, LC3 detaches from the autophagosome membrane via the 
action of ATG4 and is thus released into the cytosol [176]. This pathway may be inhibited by 
Bcl-2, an anti-apoptotic protein which binds to beclin-1, thus inhibiting the formation of the pre-
initiation complex [9]. Autophagy is a protective mechanism employed by the cell; however, its 
role in cancers is complex. Indeed, the autophagic pathway may exhibit both oncogenic or 
tumor suppressive roles based on the context [177]. 
 
Cross-talk between autophagy and apoptosis: 
Autophagic and apoptotic pathways share multiple common mediators and these 
pathways are not independent of each other [178]. The interplay of these pathways is important 
in deciding the fate of the cancer cell. In one scenario, autophagy and apoptosis can 
cooperatively induce cell death. In another situation, autophagy can antagonize apoptotic cell 
death or in some cases facilitate apoptotic cell death [178]. Several cancer therapeutic 
strategies are designed for targeting or modulating these pathways; however, the impact of one 
pathway over the other should be an important consideration when designing therapeutic 
targets. 
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Hypothesis and Aims 
It is well established that the 3q26 region contains amplified genes such as EVI1 and 
SnoN in a variety of epithelial cancers, including ovarian and breast cancer. The functional role 
of these TGF transcriptional repressors in modulating specific hallmarks of ovarian and breast 
cancers, specifically EMT and migration have not yet been investigated. The mechanism by 
which SnoN is induced following As2O3 treatment in ovarian cancer cells is unclear. It is 
unknown whether miRNAs are involved in this pathway. Additionally, we propose that loss of 
miRNAs at the 14q32 genomic cluster in renal cancer may modulate the biology of this disease. 
Thus our overall hypothesis is that “genes located at 3q26 and 14q32 contribute to the 
pathophysiology of ovarian and renal cancer, respectively.” We will address the hypothesis via 
the following specific aims:    
 
Specific aim 1 (presented in Chapter 3): We will test whether EVI1 splice variants modulate 
epithelial-mesenchymal transition by assessing expression of EMT markers and the cellular 
migratory potential.    
 
Specific aim 2 (presented in Chapter 4): We will test whether As2O3 modulates SnoN levels in a 
miRNA-dependent manner. 
 
Specific aim 3 (presented in Chapter 5): We will test whether the expression of miR-494 
(located at 14q32 locus, which is lost in renal cancer) alters renal cancer cell survival. 
 
Overall Impact and Significance 
At the end of this work, our findings will allow us to better understand the contribution of 
EVI1 and its splice variants in EMT. Further, an understanding of the mechanism by which 
SnoN becomes induced upon As2O3 treatment, will allow us to understand chemotherapeutic 
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resistance in ovarian cancer cells, which is presently unclear. Since renal cancers are 
characterized by 14q loss and miR-494 is one of 54 miRNAs located at this region, this will 
provide an incentive to further investigate this locus and understand its role in the biology of 
renal cancer.  
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Chapter 2 
 
Materials and Methods 
 
Cell Culture, Maintenance, and Propagation 
Table 2: List of cell lines utilized for dissertation 
  
Name of 
Cell Line Tissue of Origin Media 
Passage 
Number Obtained From 
T29 
Large T antigen/hTERT 
immortalized normal 
ovarian surface epithelial cells 
RPMI p=n+8 
Dr. Gordon B Mills,
MD Anderson 
Cancer Center 
T80 
Large T antigen/hTERT 
immortalized normal 
ovarian surface epithelial cells 
RPMI p=n+17 
Dr. Gordon B Mills,
MD Anderson 
Cancer Center 
 
OVCAR8 
 
Ovarian serous epithelial carcinoma RPMI p=n+5 
Dr. Gordon B Mills,
MD Anderson 
Cancer Center 
HEY Ovarian serous epithelial carcinoma RPMI p=n+9- n+30 
Dr. Gordon B Mills,
MD Anderson 
Cancer Center 
MDA-MB-
231 
Mammary epithelial adenocarcinoma 
cells RPMI 
p=n+6- 
n+12 ATCC 
 
HEK293T 
 
Human embryonic kidney epithelial 
cells RPMI 
p=n+4- 
n+12 
Dr. Gordon B Mills,
MD Anderson 
Cancer Center 
 
HK-2 
 
HPV-16 transformed normal 
kidney cortex/proximal tubule cells 
K-SFM 
(supplemented 
with BPE and 
EGF) 
p=n+2- 
n+5 ATCC 
 
769-P 
 
Epithelial renal adenocarcinoma cells RPMI p=31-42 ATCC 
 
786-0 
 
Epithelial renal adenocarcinoma cells RPMI p=111-114 ATCC 
 
A-498 
 
Epithelial renal adenocarcinoma cells EMEM p=36-38 ATCC 
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A summary of the cell lines used in this dissertation is presented in Table 2 along with 
information regarding media conditions, passage numbers, and source. All the cell lines 
reported in this study were maintained in an incubator at 370C with 5% CO2. With the exception 
of HK-2 and A-498 cells, all other cell lines were cultured in RPMI 1640 media (HyClone, Fisher 
Scientific, Pittsburg, PA), supplemented with 8% fetal bovine serum (FBS) and 5% 
penicillin/streptomycin. HK-2 cells were maintained in bovine pituitary extract and epidermal 
growth factor containing keratinocyte media (Gibco, Life Technologies, Grand Island, NY), 
supplemented with 5% penicillin/streptomycin. A-498 cells were grown in EMEM media (ATCC, 
Manassas, VA) supplemented with 8% fetal bovine serum (FBS) and 5% penicillin/streptomycin. 
For the purpose of sub-culturing, seeding or passaging cells, cells were trypsinized using 1 ml 
(T25 flask) or 2 mls (T75 flask) Trypsin/EDTA, followed by neutralization in the respective 
media. Cells were then centrifuged at 1000 rpm for 5 minutes at room temperature. The 
supernatant was discarded and the pellet re-suspended in the appropriate amount of fresh 
media. For sub-culturing of HK-2 cells, 1:5 Trypsin/EDTA solution was utilized and neutralized in 
5% FBS in PBS solution. 769-P cells were passaged at a ratio of 1:3. All other cell lines were 
passaged at a ratio of 1:4.  
 
Cloning of Bcl-2 into pBABE-puro and pQCXIN Plasmids  
Bcl-2 sequence was excised using EcoRI from pcDNA3 plasmid (Addgene Plasmid 
#19279, Cambridge, MA, deposited by Dr. Philip Leder) [179] and cloned into pBABE-puro and 
pQCXIN plasmids using the following cloning strategy. The excised sequence of Bcl-2 was run 
on a 1% agarose gel, following which gel purification (QIAquick Gel Extraction Kit, Qiagen, 
#28706) was carried out to retrieve the insert in 30 l of EB buffer. Heat inactivation and vector 
dephosphorylation step for each of the plasmid was performed. Ligation was carried out using 
10 l of the insert, 1 l of the dephosphorylated vectors, 1 l enzyme and 10 l ligation buffer. 
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The mixture was incubated at room temperature for 5 minutes and at 40C for 1 hour. Following 
ligation, transformation was performed in Top10F’ bacteria. Bacterial colonies were selected 
and the positive transformants were subjected to restriction digestion by Sac II to determine 
correct orientation. The constructs were then sent for sequencing at the Molecular Genomics 
Core, Moffitt Cancer center, Tampa, FL.  
 
Generation of Retroviral Stable Cell Lines 
T29 and OVCAR8 cells were utilized for the generation of retroviral cell lines stably 
expressing either control, EVI1 wild-type (WT), EVI1Del427-515, or EVI1Del190-515 sequence cloned 
into pLEGFP-C1 plasmid [14]. HEK 293T cells were used as the packaging cell line and were 
seeded in 6-well plates at 1.5 million cells/well. Following 24 hour overnight adherence of the 
cells to the culture dish, the media in the wells was replaced with 2 mls of serum-free media. 
The transfection mixture (per transfection) was prepared by adding 100 l serum-free media to 
cryovials, following which, 1 g of plasmids (pCGP, pVSVG, and the pLEGFP-C1 plasmids in 
the ratio 1:1:1) and 3 l Fugene HD (Promega, Madison, WI) were added. This transfection 
mixture was allowed to incubate at room temperature for 15 minutes, following which it was 
added dropwise onto the cells. The cells were then overlayed with 2 mls of complete media 6 
hours post-transfection. The following day, media from the wells was replaced with 2 mls of 
complete media. On the same day, T29 and OVCAR8 cells were seeded at 250,000 cells/well. 
Twenty-four hours after seeding, the first round of infection was performed by replacing the 
media in the wells with supernatant containing viruses from HEK293T cells along with polybrene 
(8 g/ml) (the viral media was filtered using a 0.45 m filter before application). Two mls of 
complete media was added to the HEK293T cells plate. The following day, a second round of 
infection was performed as described above. Twenty-four hours post the second infection, 
media in the wells was replaced by 2 mls of complete media and the following day G418 
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containing media was added to the wells (the concentration of G418 utilized for T29 cells was 1 
mg/ml and OVCAR8 cells was 0.1 mg/ml) in order to apply selection pressure. The cells were 
monitored for growth and viability. Media was replaced periodically, as required. Once confluent, 
they were expanded to a T25 or T75 flask, as appropriate and subsequently frozen. 
The pBABE-puro-mCherry-GFP-LC3B plasmid was obtained from Addgene (Plasmid 
#22418, Addgene, Cambridge, MA, deposited by Dr. Jayanta Debnath) [180]. For the purpose 
of generating 769-P cells stably expressing mCherry-GFP-LC3B (two independent retroviral 
pools), a similar protocol was followed, with some changes. One million 769-P cells were 
seeded for the infection and only one round of infection was performed. Cells were recovered 
with 2 mls of complete media 24 hours post-infection; 3 hours post-recovery, cells were 
trypsinized and expanded to a T25 flask. The next day, 0.75 g/ml puromycin containing media 
was added to the wells and cells were monitored for growth and viability. Once cells were 
confluent, they were expanded and subsequently frozen down for storage. 
769-P parental and 769-P mCherry-GFP-LC3B cells stably expressing Bcl-2 were also 
established utilizing pBABE-puro-Bcl-2 and pQCXIN-Bcl2 plasmids, respectively. The protocol 
for retroviral stable cell line generation was identical to the one described above for 769-P cells. 
For the selection with pQCXIN plasmid, G418 was utilized at a concentration of 0.5 mg/ml in 
addition to puromycin at 0.75 g/ml (since it was double gene overexpressing cell line – 
mCherry-GFP-LC3B and Bcl-2).  
 
Treatment with Drugs  
As2O3 and TGF were used in the present study. NaOH and nanopure water were used 
to dissolve As2O3 (Sigma-Aldrich, St. Louis, MO) to prepare a working stock of 5 mM, which was 
further also filter sterilized using a 0.2 m filter. TGFCalbiochem, Rockland, MA was used at 
a concentration of 50 pM and was prepared in 500 l of 0.1% BSA and 4 mM HCl. 
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miRNA Mimic/Inhibitor Transfection 
For transfection with miRNA mimic or inhibitor, 250,000 cells were seeded in 6-well 
plates. Following 24 hours adherence, cells were transfected with either mimic (Negative control 
miRNA mimic, #4464058; hsa-miR-216b, #4464066, MC12302; hsa-miR-410, #4464066, 
MC11119; hsa-miR-494, #4464066, MC12409;  and/or hsa-miR-495, #4464066, MC11526 
mimic) or inhibitor (Negative control miRNA inhibitor, #4464076; hsa-miR-494 inhibitor, 
#4464084, MH12409), or both, at a concentration of 200 pmol. The mimics and inhibitors 
utilized in the study were obtained from Life Technologies, Grand Island, NY. For transfection 
(per well), 100 l serum-free media was added to cryovials following 200 pmol (4 l) 
mimic/inhibitor and 3 l Fugene HD (Promega, Madison, WI). This transfection mixture was 
allowed to incubate at room temperature for 15 minutes, following which it was added dropwise 
in a spiral manner onto the wells. Cells were overlayed with complete media, 6 hours post-
transfection. Following 24 hours post-transfection, cells were trypsinized, counted, and re-
seeded at 250,000 cells/well. They were processed at 24, 48, 72, or 96 hours post-transfection 
with or without drug/inhibitor treatment (indicated in a separate section). Mimic/inhibitor 
transfection was also performed in 24-well plates with an initial cell seeding number of 50,000 
cells/well. The procedure was similar as described above; however, all the volumes were 
reduced 5 times and the re-seeding step was omitted.  
 
siRNA Transfection Strategies 
Cells were seeded in complete media at different densities depending on the cell type 
(as described below, in detail) in 6-well plates or 35 mm dishes for siRNA-mediated knockdown 
experiments. After overnight adherence, complete media from the wells was replaced with 370C 
pre-warmed serum-free media. Transfection mixture (per transfection) was prepared in 
eppendorf tubes by adding 100 l serum-free media and 4 l Dharmafect transfection reagent 
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(Dharmacon, GE Healthcare, Lafayette, CO). This mixture was allowed to incubate at room 
temperature for 10 minutes following which 5 l (50 nM) of the respective siRNA (obtained from 
Dharmacon GE Healthcare, Lafayette, CO) was added to the tubes and incubated at room 
temperature for 20 minutes. This transfection mixture was then added dropwise onto the cells 
followed by overlaying with complete media after 3 hours. Twenty-four hours post the first 
siRNA transfection, media from the wells was removed and replaced with complete media. 
Following a 3 hour recovery period, another round of siRNA transfection was performed as 
described above. Twenty-four hours post the second round of siRNA transfection, cells were 
recovered by replacing the media in the wells with complete media. The cells were then either 
re-seeded 24 hours or harvested 48 hours post the second transfection (depending on 
experiment type). siRNA knockdown with minor variations across various experiments are 
indicated as follows: 
1. For the purpose of miRNA isolation in order to quantify miR-200a/b/c members, 2 million MDA- 
MB-231 and 650,000 HEY cells were seeded in 60 mm dishes. siRNA transfection was 
performed (non-targeting ON-TARGETplus control siRNA and siME) as described above except 
the quantities were doubled for the 60 mm dishes. 
2. In order to isolate total RNA for quantification of relative mRNA levels or protein analysis, 1 
million MDA-MB-231 and 325,000 HEY cells were seeded in 6-well plates. siRNA transfection 
(mock, non-targeting ON-TARGETplus control siRNA, siB, si2Kb, si04, and siME) was 
performed as described above. 
3. 769-P cells were seeded at 750,000 cells/well. siRNA transfection (non-targeting ON-
TARGETplus control siRNA, Ago2, ATG7, Bcl-2, or LC3B) was performed as described above. 
For transfection involving Bcl-2 siRNA, a concentration of 100 nM was utilized, instead of 50 
nM.   
A list of siRNAs utilized in the present study obtained from Dharmacon (GE Healthcare, 
Lafayette, CO) are summarized in Table 3 along with their catalog numbers. 
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Table 3: List of siRNA target genes utilized for dissertation 
siRNA Catalog number 
Ago2 L-004639-00 
ATG7 L-020112-00 
Bcl-2 L-003307-00 
Non-targeting  ON-TARGETPlus control D-001810-10 
LC3B L-012846-00 
 
 
siRNA targeting various splice variants of EVI1 (siB, si2Kb, si04, siME) were custom 
designed by Dharmacon (GE Healthcare, Lafayette, CO), according to a study conducted by 
Jazaeri and colleagues [3]. EVI1 siB reduced the protein expression of WT EVI1, MDS1/EVI1, 
and EVI1Del190-515; EVI1 si2Kb reduced the protein expression of EVI1Del190-515; EVI1 si04 reduced 
the protein expression of MDS1/EVI1; and EVI1 siME reduced the protein expression of 
MDS1/EVI1and EVI1Del190-515. 
 
Dual Transfection with siRNA and Mimic 
For co-transfection experiments with siRNA and mimic, cells were seeded and siRNA 
transfection conducted as described above. Following 24 hours of a second round of siRNA 
transfection, cells were recovered for 3 hours and then trypsinized, counted, and re-seeded at 
250,000 cells/well. Twenty-four hours post re-seeding, cells were transfected with mimic, as 
described above. Cells were processed at 72 hours post-mimic transfection. 
 
Indirect Immunofluorescence 
769-P cells were seeded at 250,000 cells/well. Cells were transfected using control or 
miR-494 mimic, as described above. Twenty-four hours post-transfection, 150,000 cells were 
re-seeded onto glass coverslips. Ninety-six hours post-transfection, the cells were rinsed in PBS 
and fixed using 4% paraformaldehyde (in PBS) for 30 minutes at room temperature (for 
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experiments involving co-staining with LC3B and another antibody, fixation was performed for 
15 minutes with 4% paraformaldehyde at room temperature, followed by 15 minutes in ice-cold 
100% methanol at -200C). Following fixation, two PBS washes were conducted for 5 minutes 
each, after which the cells were blocked for 1 hour at room temperature in PBS solution with 5% 
goat serum and 0.1% Triton X-100. After the blocking step, two PBS washes were performed (5 
minutes each). Now, primary antibody application was performed by placing the coverslips in 
petri dishes onto 50 l primary antibody (prepared in PBS solution with 1% goat serum, 0.1% 
Triton X-100, and the appropriate primary antibody dilution). These petri dishes were then 
placed in a humidified chamber and left overnight at 40C.  
The next day, coverslips were placed into 6-well plates with fresh PBS solution, followed 
by two 5 minute PBS washes. Five hundred l/well of secondary antibody was applied to the 
wells and incubated at room temperature for 1 hour. The secondary antibody solution was 
prepared in PBS solution with 1% goat serum, 0.1% Triton X-100, and 1:500 dilution of goat 
anti-rabbit Alexa Fluor-546 (#A11035, Life Technologies, Grand Island, NY) or goat anti-mouse 
Alexa Fluor-488 (#A11029, Invitrogen, Life Technologies, Grand Island, NY) secondary 
antibody. Following secondary antibody application, three 5 minute PBS washes were 
performed. Following this, for experiments involving co-staining utilizing two different antibodies, 
the second primary antibody was applied as described above. If not, the coverslips were 
mounted on glass slides onto mounting media containing DAPI for staining the nucleus. Images 
were captured using a Perkin Elmer Confocal Spinning Disc Microscope (CMMB Core Facility, 
University of South Florida, Tampa, FL). (For immunofluorescence experiments involving both 
siRNA and mimic transfection, 250,000 cells were re-seeded per well on glass coverslips after 
the co-transfection and an identical protocol was followed as described in the above section). A 
list of antibodies and related information utilized for this section is summarized in Table 4. 
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Table 4: List of primary antibodies utilized for immunofluorescence analyses 
 
Antibody Dilution Category Company Catalog number 
AIF 1:400 Rabbit monoclonal Cell Signaling Technology #5318 
Cytochrome c 1:250 Mouse monoclonal Cell Signaling Technology #12963 
Drp1 1:50 Rabbit monoclonal Cell Signaling Technology #8570 
LC3B 1:400 Rabbit polyclonal Cell Signaling Technology #2775 
 
 
EGFP-LC3B Immunofluorescence Studies 
HEY cells were seeded at 250,000 cells/well in 6-well plates. After 24 hours, cells were 
transfected with control or miR-494 mimic, as described above. Twenty-four hours post-
transfection, cells were re-seeded onto glass coverslips. Following a 24 hour period of 
adherence, cells were transfected with 1 g/well pEGFP-LC3B plasmid (Addgene Plasmid 
#24920, Cambridge, MA, deposited by Dr. Toren Finkel) [181], using Fugene HD as transfection 
reagent.  At 72 hours post mimic transfection, cells were treated with 10 M As2O3 for 18 hours 
following which they were fixed, blocked, and mounted onto glass slides with DAPI at 96 hours 
post-mimic transfection. Images were captured using a Zeiss inverted fluorescent microscope 
(Analytic Microscopy Core, Moffitt Cancer Center, Tampa, FL).  
769-P cells, seeded on glass coverslips were transfected with miR-494 mimic, as 
described above. Forty-eight hours post-transfection, cells were transfected with pEGFP-LC3B 
plasmid, as described. Cells were then treated with 25 M CQ (for 18 hours) at 72 hours post-
mimic transfection. At 96 hours post-mimic transfection, cells were processed as mentioned 
above and images were captured using a Perkin Elmer Confocal Spinning Disc Microscope 
(CMMB Core Facility, University of South Florida, Tampa, FL).   
For studies involving Bcl-2 siRNA, 769-P cells were seeded at 500,000 cells/well on 
glass coverslips. After 24 hour overnight adherence, Bcl-2 siRNA transfection was performed as 
described above (only one round of transfection performed at a concentration of 100 nM). 
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EGFP-LC3B plasmid transfection was then performed at 24 hours post-transfection. The next 
day, cells were processed as described above and imaged using a Perkin Elmer Confocal 
Spinning Disc Microscope (CMMB Core Facility, University of South Florida, Tampa, FL).   
 
Assessing Transfection Efficiency Using pEGFP-C1 
Following seeding of HK-2, 769-P, 786-O, and A-498 cells at 250,000 cells/well on glass 
coverslips, they were transfected with 1 g pEGFP-C1 plasmid (Clonetech, CA), using Fugene 
HD as transfection reagent, as described above. Forty-eight hours post-transfection, cells were 
fixed, blocked, and coverslips were mounted on glass slides with DAPI mounting media. Images 
were captured using the Perkin Elmer Confocal Spinning Disc Microscope (CMMB Core Facility, 
University of South Florida, Tampa, FL). 
 
mCherry-GFP-LC3B Flux Assay and Macro Image J Analysis 
769-P cells stably expressing mCherry-GFP-LC3B fusion protein, (both retroviral cell 
lines 1 and 2) were seeded at 250,000 cells/well in a 6-well plate. Control and miR-494 mimic 
transfection were performed, as stated above. Twenty-four hours post-transfection, cells were 
recovered and re-seeded at 250,000 cells/well for protein harvest (western blot validation 
analysis) and 150,000 cells/well on glass coverslips for immunofluorescence analysis. Ninety-
six hours post-transfection, cells were fixed, blocked, and coverslips were then mounted on 
glass slides in mounting media containing DAPI. Images were captured using the Perkin Elmer 
Confocal Spinning Disc Microscope (CMMB Core Facility, University of South Florida, Tampa, 
FL). Ten images per sample were captured for a total of 30 images for the control mimic and 30 
images for miR-494 mimic transfected cells for each retroviral cell line (1 and 2). The images 
were subjected to Image J macro analysis, a program that automatically divides the merged 
figure into separate green, red, and merged images and quantifies the number and area of 
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punctae [182]. The macro data was then further analyzed to obtain average values as well as 
number of punctae/cell and punctae area/cell for the green, red, and merged punctae.   
 
Total RNA Isolation and Quantitative Real-Time PCR 
For isolating total RNA, RNeasy mini kit was utilized from Qiagen (Valencia, CA) and 
RNA isolation was carried out according to the manufacturer’s instructions. RNA concentration 
and purity was quantified using Nanodrop (Thermo Scientific, Hudson, New Hampshire). 
Quantitative real-time PCR analysis was performed using One-step TaqMan master mix and 
probes/primers obtained from Applied Biosystems (Grand Island, NY). The following 
probes/primers were obtained from Applied Biosystems Assays-on-Demand: E-Cadherin 
(Hs01023894); Claudin 1 (Hs00221623); LC3B (Hs00797944_s1); N-Cadherin (Hs00983056); 
PRKAG2 (Hs00211903_m1); Snail (Hs00195591); SnoN (Hs00180524_m1); Slug 
((Hs00950344); Twist (Hs00361186); ZEB1 (Hs00232783); and ZEB2 (Hs00207691). The 
correlative method was utilized to calculate RNA-fold changes from CT of genes using β-actin as 
the endogenous control.  
 
miRNA Isolation and Quantitative Real-Time PCR 
Total RNA isolation was carried out according to the manufacturer’s protocol provided 
with the mirVana miRNA isolation kit from Ambion (NY, USA). Briefly, cells were washed with 
PBS and then an appropriate volume of the lysis/binding solution was added. Lysates were 
collected and one tenth the volume of miRNA homogenate additive was added followed by an 
incubation on ice for 10 minutes. Acid-phenol:chloroform, equal to the amount of lysis/binding 
buffer was then added and the mixture was vortexed for 30–60 seconds. The samples were 
then centrifuged for 10 minutes at 10,000 g at room temperature in order to separate the 
aqueous and organic phases. An appropriate volume of the aqueous (upper) phase was 
carefully collected. The volume was recorded and then 1.25 times this amount of room 
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temperature 100% ethanol was added to the aqueous phase, recovered from the previous 
organic extraction step. For each sample, a filter cartridge was placed into the collection tubes 
and the lysate/ethanol mixture (from the previous step) was added onto the filter cartridge.  The 
mixture was centrifuged for ~15 seconds at 10,000 g and the flow-through was discarded. 
Seven hundred l miRNA wash solution 1 was added and centrifuge for ~5–10 seconds at the 
same speed. The flow-through was discarded. Now, 500 l of wash solution 2/3 was added and 
centrifuged for ~15 seconds for 10,000 g. This step was repeated and after discarding the flow-
through from the last wash, the filter cartridge was replaced and the assembly was centrifuged 
for 1 minute (twice) to remove residual fluid from the filter. Now the filter cartridge was 
transferred into a fresh collection tube and RNA eluted in 25 l of pre-heated (950C) nuclease-
free water and quantified using Nanodrop.  
The reverse transcription reaction and PCR was performed according to the 
manufacturer’s protocol (TaqMan MicroRNA Assays, Applied Biosystems, NY, USA). The 
probes/primers for both the reverse transcription and PCR reaction were obtained from Applied 
Biosystems Assays-on-Demand: hsa-miR-200a, RT:000502, TM:000502; hsa-miR-200b, 
RT:002251, TM:002251; hsa-miR-200c, RT:002300, TM:002300; hsa-miR-494, RT:002365, 
TM:002365; and RNU6B, RT:001093, TM:001093. The “RT” stands for probes/primers for the 
reverse transcription reaction and “TM” stands for those used for the PCR reaction. The RT 
reaction cycle conditions were as follows: 30 minutes at 160C, 30 minutes at 420C, and 5 
minutes at 850C. The cycle conditions for PCR were as follows: 950C for 10 minutes, followed 
by 50 cycles of 15 seconds at 950C and 1 minute at 600C.  Correlative method was utilized to 
calculate RNA-fold changes as CT of genes using RNU6B as the endogenous control.  
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Protein Isolation and Western Blotting Analysis 
In order to isolate protein, cells were lysed for 1 hour in the appropriate volume 
(depending on cell density at the time of harvest) of lysis buffer. The lysis buffer solution was 
prepared in Nanopure water and is composed of 150 mM NaCl, 1 mM MgCl2, 1 mM EGTA, 50 
mM HEPES, 1% Triton X-100, 10% glycerol, and protease inhibitor tablet (Roche, Madison, WI). 
Following 1 hour lysis, cells were gently scraped, collected into eppendorf tubes and centrifuged 
at 14,000 rpm for 10 minutes at 40C. Supernatant was collected and protein concentration was 
calculated using the Bicinchoninic Assay (BCA) Kit (Pierce, Fischer Scientific, Pittsburgh, PA). 
Protein concentration was normalized to the lowest sample. A total of 10 l 6X SDS dye was 
added to 50 l sample (diluted in lysis buffer) and 20 l was loaded into the wells. Samples 
were run on appropriate percent (8, 10, or 12%) of SDS-PAGE (sodium dodecyl sulphate – 
polyacrylamide gel electrophoresis) gel. The gel was run typically for 2 hours at a constant 
voltage of 100 Volts following which gels were transferred to PVDF (polyvinylidine difluoride) 
membrane using a semi-dry transfer apparatus (Bio-Rad, Hercules, CA). The transfer settings 
for 1 gel utilized were at 0.11 Amps (or 0.15 Amps for 2 gels) for 2 hours. The membranes were 
then washed for 10 minutes in TBST (Tris-buffered saline containing 0.1% Tween-20, Bio-Rad, 
Hercules, CA) buffer on an orbital shaker (Thermo Scientific, Hudson, New Hampshire). Next, 
membranes were blocked for 1 hour in 5% milk prepared in TBST. After blocking, they were 
rinsed in TBST and primary antibody solution was applied (prepared in 5% bovine serum 
albumin (Fraction V heat-shock treated, #BP1600-100, Fisher Scientific, Waltham, MA) in 
TBST) and incubated overnight on an orbital shaker at 40C. The next day, the primary antibody 
was collected and 15 minute washes in TBST were performed for 1 hour, following which HRP-
conjugated secondary antibody in 5% milk (prepared in TBST) was applied. The secondary 
antibody was either goat anti-rabbit (#107-5046, Immun-Star, Biorad, Hercules, CA), goat anti-
mouse (#107-5047, Immun-Star, Biorad, Hercules, CA), or donkey anti-goat (sc-2020, Santa 
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Cruz Biotechnology, Santa Cruz, CA) as appropriate. After the 1 hour secondary antibody 
incubation, 15 minute washes were performed for 1 hour and 30 minutes. Enhanced 
chemiluminescence solution (Immun-Star, Bio-Rad, Hercules, CA or LumiGLO, Cell Signaling, 
Danvers, MA) was then applied on the membranes prior to exposure of the membrane to X-ray 
film in order to detect bound antibodies. A list of antibodies utilized in the current study are 
summarized in Table 5. 
 
Table 5: List of primary antibodies utilized for western blotting analyses 
 
Antibody Dilution Category Company Catalog number 
Ago2 1:500 Rabbit monoclonal Cell Signaling Technology #2897 
ATG7 1:1000 Rabbit polyclonal MBL International PM039 
Bcl-2 1:500 Rabbit monoclonal Cell Signaling Technology #2870 
Bcl-2 1:1000 Rabbit monoclonal Cell Signaling Technology #4223 
Caspase 2 1:1000 Mouse monoclonal Cell Signaling Technology #12675 
Caspase 3 1:1000 Rabbit monoclonal Cell Signaling Technology #12675 
Caspase 8 1:1000 Mouse monoclonal Cell Signaling Technology #12675 
Caspase 9 1:1000 Mouse monoclonal Cell Signaling Technology #12675 
Claudin-1 1:4000 Rabbit polyclonal Life Technologies 187362 
Cyclin E1 1:500 Mouse monoclonal Santa Cruz Biotechnology sc-247 
Drp1 1:1000 Rabbit monoclonal Cell Signaling Technology #8570 
EVI1 1:1000 Rabbit monoclonal Cell Signaling Technology #2593 
GAPDH 1:4000 Rabbit polyclonal Cell Signaling Technology #2118 
GFP 1:1000 Mouse monoclonal Santa Cruz Biotechnology sc-9996 
LC3B 1:1000 Rabbit polyclonal Cell Signaling Technology #2775 
N-Cadherin 1:500 Rabbit polyclonal Cell Signaling Technology #4061 
Pan Actin 1:1000 Rabbit polyclonal Cell Signaling Technology #4968 
PARP 1:1000 Rabbit polyclonal Cell Signaling Technology #9542 
PINK1 1:500 Rabbit monoclonal Cell Signaling Technology #6946 
SnoN 1:1000 Rabbit polyclonal Santa Cruz Biotechnology sc-914 
 
 
Reverse Phase Protein Array (RPPA)  
T29 and OVCAR8 retroviral stable cells overexpressing EVI1 splice variants were 
seeded at 500,000 and 1 million cells, respectively, and treated with TGFat a concentration of 
50 pM for various time points (0 hour, 5 minutes, 1, 3, 6, and 24 hours). Cell protein lysates 
were harvested as described above and samples were sent to MD Anderson Cancer Center 
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(Houston, Texas) for analysis. RPPA analysis was performed as described by Nanjundan and 
colleagues [183]. Briefly, Aushon arrayer was utilized to print protein lysate arrays on 
nitrocellulose-coated glass FAST slides. An automated DAKO autostainer was utilized to 
perform staining of the validated primary antibodies and data was quantified using the 
Supercurve method [183]. 
 
Cell Viability Assay Using Crystal Violet  
HEY or 769-P cells were seeded at 250,000 cells/well in a 6-well plate. Following 24 
hour adherence, they were transfected with control or miR-494 mimic. Twenty-four hours post- 
transfection, cells were re-seeded at 5,000 cells/well in a transparent 96-well plate. At 96 hours 
post-transfection, (with or without 25 M As2O3 treatment  for 18 hours), media was removed 
from the plates and 100 l crystal violet staining solution was added and washed with Nanopure 
water after 15-20 minutes. Following overnight drying, 200 l of Sorenson’s buffer was added to 
the wells and the viability was assessed by reading the absorbance at 570 nm on a Biotek plate 
reader [184].  
 
Lactate Dehydrogenase (LDH) Cytotoxicity Assay (Necrosis Assay) 
769-P cells were seeded at 250,000 cells/well in a 6-well plate. Following 24 hour 
adherence, they were transfected with control or miR-494 mimic. Twenty-four hours post- 
transfection, cells were re-seeded at 25,000 cells/well in a 96-well plate. Following overnight 
adherence, the media in the wells was replaced with 200 l of 1% FBS-media. Ninety-six hours 
post-transfection, the plate was pulse centrifuged to bring the contents to the bottom of the well. 
Following this, 100 l of media was removed from the wells and transferred to a new opaque 
plate. One-hundred l aliquot of the catalyst and dye (Roche, CA, USA) was added to the wells. 
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The plate was then shaken for 1 hour in the dark. The plate was incubated in the dark for 30 
minutes and absorbance read at 490 nm on a Biotek plate reader.  
 
Migration Assay Using Boyden Chambers 
HEY and MDA-MB-231 cells were seeded at 325,000 and 1 million cells/well in a 6-well 
plate. Following two rounds of siRNA transfections (as described above), cells were trypsinized 
and re-seeded at 25,000 cells/well in 500 l serum-free media in the top insert of a 24-well 
Boyden chamber insert plate. The bottom chamber was filled with 750 l of complete media 
(containing serum as chemoattractant). Twenty-four hours post re-seeding, media was removed 
from the inserts and a cotton swab was used to wipe away the cells from the inside of the insert 
membrane. One ml crystal violet staining solution was then added to the inserts. Following 20 
minutes incubation, the inserts were washed with Nanopure water. A cotton swab was used to 
carefully dry out the inserts after which they were transferred to a fresh 24-well plate and the 
cells were counted under a bright field light microscope.  
 
Apoptosis Assay 
The apoptosis assay was performed using the annexin V-FITC Apoptosis Detection Kit 
(#PF032) from Millipore, Billerica, MA. Following appropriate treatments and transfection, both 
floating and adherent (released by trypsinization) cells were collected from each well of a 6-well 
plate. The cells were centrifuged at a speed of 1,000 rpm for 5 minutes. After removing the 
supernatant, the pellet was re-suspended in 500 l of PBS. Ten l media-binding buffer was 
added to the tubes along with 1.25 l annexin-V/FITC. The samples were incubated for 15 
minutes at room temperature in the dark. The samples were then centrifuged at 1,000 g for 5 
minutes. The supernatant was discarded and 500 l of binding buffer was added along with 10 
l PI (propidium iodide). The samples were then incubated for 30 minutes in the dark at which 
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time they were transferred to flow cytometry tubes for analysis (Karoly Szekeres, College of 
Medicine, Flow cytometry core, University of South Florida, Tampa, FL).  
 
Cell Cycle Analysis 
HEY cells were seeded at 250,000 cells/well in a 6-well plate. Following 24 hour 
adherence, they were transfected with control or miR-494 mimic. Twenty-four hours post-
transfection, cells were re-seeded at 25,000 cells/well in a 6-well plate. Ninety-six hours post- 
mimic transfection, floating cells were collected and the adherent cells were trypsinized and 
collected in the same tube that had the floating cells. The cells were centrifuged at 1,000 rpm for 
5 minutes. The supernatant was removed and pellet re-suspended in 1 ml PBS. In a separate 
set of tubes, 9 mls of 70% ethanol (prepared in PBS) was added. The cells resuspended in PBS 
were added to the 9 mls of 70% ethanol dropwise with gentle vortexing. The tubes were then 
placed at -200C overnight. The next day, the samples were centrifuged at 1,000 rpm at 40C for 
10 minutes. The supernatant was discarded and the pellet was re-suspended in 3 mls of ice 
cold PBS. The centrifugation was repeated and the pellet was re-suspended in 500 l of PI 
staining solution, containing 500 g/ml PI, 0.5% Triton X-100, and DNAase-free RNAase A 
(prepared in PBS). The samples were placed for 30 minutes at room temperature and then 
analyzed (Karoly Szekeres, College of Medicine, Flow cytometry core, University of South 
Florida, Tampa, FL).   
 
Colony Formation Assay 
769-P cells were seeded at 250,000 cells/well in a 6-well plate. Following 24 hour 
adherence, they were transfected with control or miR-494 mimic. Twenty-four hours post- 
transfection, cells were re-seeded at 5,000 cells/well in a 6-well plate. Following 2 weeks, cells 
were stained with crystal violet.  
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Cholesterol Measurements 
Cholesterol was measured using the Amplex Red Cholesterol Assay Kit (#A12216, Life 
Technologies, Grand Island, NY) and the assay was performed according to the manufacturer’s 
instructions. Briefly, 769-P cells were seeded, transfected, and protein harvested as described 
above. Protein samples were all normalized to the sample with the lowest concentration. The 
samples were added to the wells of a black opaque 96-well plate in a 2:3 ratio with 1X reaction 
buffer, provided with the kit (total 50 l). Cholesterol standards used for the assay were 0. 0.5, 
1.0, 2.5, 5.0, 7.5, and 10 g/ml. Fifty l of each of these standards was added to the 96-well 
plate. Lysis buffer and 1X reaction buffer in the ratio 2:3 was used as a negative control. Fifty l 
of 10 M H2O2 (hydrogen peroxide) was used as a positive control. Then, 50 l of the Amplex 
Red working solution was added to each well and the plate was incubated in the dark at 370C 
for 30 minutes, following which fluorescent readings were measured at 528/20 (excitation), 
590/35 (emission) on a Biotek plate reader.    
 
LipidTOX Neutral Lipid Staining 
769-P cells were seeded into 6-well plates followed by siRNA and/or miRNA mimic 
transfections which were performed as described above. Cells were re-seeded at 150,000 
cells/well (if transfected with mimic only) or 250,000 cells/well (if transfected with both siRNA 
and mimic) on glass coverslips. Seventy-two (if transfected with siRNA and mimic) or 96 hours 
(if transfected with mimic only) post-mimic transfection, cells were rinsed with PBS and fixed 
using 4% paraformaldehyde for 30 minutes at room temperature. Two PBS washes (5 minutes 
each) were performed, following which a 1:200 dilution of the LipidTOX green neutral lipid stain 
(#H34475, Life Technologies, Grand Island, NY) in PBS was added to the wells. Coverslips 
were mounted onto glass slides with DAPI and images were captured using the Perkin Elmer 
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Confocal Spinning Disc Microscope (CMMB Core Facility, University of South Florida, Tampa, 
FL). 
 
MitoSOX Assay 
Control or miR-494 mimic expressing 769-P cells were re-seeded at 150,000 cells/well 
on glass coverslips following transfection. Ninety-six hours post-transfection, complete media 
from the well was replaced with 1 ml of 5 M MitoSOX red reagent (#M36008, Life 
Technologies, Grand Island, NY) prepared in Hank’s Balanced Salt Solution (HBSS) containing 
calcium and magnesium. The cells were incubated in the above solution for 10 minutes at 370C, 
following which 3 washes (2 minutes each) were performed in HBSS. After the washes, cells 
were rinsed in PBS, followed by fixation, and blocking. Cells were further processed and imaged 
as described above. 
 
3’UTR Luciferase Assay 
Twenty-four hours post-seeding of T80 cells at 250,000 cells/well, they were transfected 
with control or miR-494 mimic and 1 g of pEZX-MT01 3’UTR luciferase plasmid (control, 
CmiT000001-MT01; Bcl-2a, HmiT016211a-MT01; Bcl-2b, HmiT016211b-MT01; LC3B, 
HmiT019948-MT01, (GeneCopoeia, Rockville, MD)) in serum-free media using Fugene HD as 
transfection reagent, as described above. Twenty-four hours post-transfection, cells were 
recovered in complete media and following a 3 hour recovery, the assay was performed 
according to the manufacturer’s instructions provided with the Luc-Pair miR Luciferase Assay 
Kit (LPFR-M010, Genecopoeia, Rockville, MD). Briefly, cells were rinsed in PBS and 100 l of 
solution I was added. The wells were scraped lightly and 50 l was added to 1 well of an 
opaque 96-well plate, already containing 50 l of solution I. Following a 10 minute incubation at 
room temperature in the dark, firefly luminescence readings were taken using the Biotek plate 
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reader. Then, 100 l of solution II was added and following a 10 minute incubation, renilla 
luminescence readings were measured. A ratio of luminescence was calculated from the firefly 
to the renilla luciferase in order to determine transfection efficiency since the 3’UTR target is 
downstream of the firefly luciferase and the renilla luciferase is for assessing efficacy of 
transfection. 
 
Luciferase Promoter Assay 
OVCAR8 cells stably expressing EVI1 constructs were seeded at 250,000 cells/well in 
G418 containing media. Twenty-four hours post seeding, cells were transfected with pGL3 
plasmid harboring claudin-1 promoter (the claudin-1 promoter was a kind gift from Dr. Yoshiaki 
Ito, Institute of Molecular and Cell Biology, Proteos, Singapore) downstream of the luciferase 
gene, following standard plasmid transfection protocol as described above. Forty-eight hours 
post transfection, protein lysates were collected and luciferase assay was performed according 
to instructions provided with the kit (Luciferase assay, #E151A, Promega, Madison, WI). 
Luminescence readings were recorded using a Biotek plate reader. 
 
RT2-PCR Pathway Focused PCR Array (Lipoprotein Signaling and Cholesterol 
Metabolism, Autophagy, and Apoptosis)  
Total RNA was isolated from 769-P cells expressing control or miR-494 mimic, as 
described above. Overall, cDNA was prepared, following which the PCR array was performed 
as per manufacturer’s instructions (Lipoprotein signaling and cholesterol metabolism, PAHS-
080Z; Autophagy, PAHS-084Z; or Apoptosis, PAHS-012Z). Each array consisted of 
probes/primers for 84 different genes, 6 housekeeping genes, 3 positive PCR controls, 3 
reverse-transcription controls, and 1 genomic DNA control. For the cDNA synthesis, two 
separate mixtures were prepared. The genomic DNA elimination mixture was prepared by 
adding 0.5 g of RNA, 2 l of Buffer GE, and the volume was made up to 10 l by adding 
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RNase-free water. Ten l of the reverse-transcription mixture was then prepared by mixing 4 l 
of 5X buffer BC3, 1 l Control P2, 2l RE3 reverse transcriptase mix, and 3 l RNase-free 
water. The genomic DNA elimination mixture was incubated at 420C for 5 minutes and placed 
immediately on ice for 1 minute, after which it was added to the reverse-transcription mixture 
and incubated at 420C for 15 minutes. Ninety-one l of RNase-free water was then added to this 
combined mixture. For the array, the PCR component mixture was prepared by adding 1350 l 
2X RT2 SYBR green master mix, 102 l cDNA synthesis reaction (as prepared above) and 1248 
l RNase-free water. Twenty-five l of this mixture was added to each well of the 96-well array 
plate. The cycling conditions used were as follows: 10 minutes at 950C followed by 40 cycles of 
15 seconds at 950C and 1 minute 600C. Additionally, melt curves were acquired to generate first 
derivative dissociation curves for each well necessary for verifying PCR specificity. The results 
from the array were analyzed using the online Qiagen analysis web tool 
(https://www.qiagen.com/us/products/genes%20and%20pathways/data-analysis-center-
overview-page/). 
 
Transmission Electron Microscopy (TEM) 
769-P cells transfected with control or miR-494 mimic in 100 mm culture dishes were 
provided to Edward Haller (Department of Integrative Biology, University of South Florida, 
Tampa, FL) at ninety-six hours post mimic transfection. The control and experimental samples 
were fixed overnight in 2.5% glutarayldehyde (with 0.1 M phosphate buffer). The next day, 
another fixation was performed for 1 hour in 1% buffered osmium tetroxide that was dehydrated 
in acetone. This was followed by embedding the samples in LX 112 epoxy resin. Thereafter, thin 
section from the blocks were subsequently stained with 8% aqueous uranyl acetate and 
Reynold’s lead citrate. Images were captured using a FEI Morgagni 268D (FEI Company, Inc, 
Hillsboro, OR) transmission electron microscope.  
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Bioinformatic Analyses 
The following programs were used to identify miRNA targets in the 3’-UTR of SnoN: 
PicTar, TargetScan, MicroCosm, PITA, miRANDA, and miRDB. In order to identify miR-494 
binding sites in the 3’UTR of HAD database genes, Human TargetScan program was used. The 
following bioinformatics programs (along with the weblinks) were utilized in the current study: 
cBioPortal for Cancer Genomics: http://www.cbioportal.org/public-portal/ 
PITA: http://genie.weizmann.ac.il/pubs/mir07/mir07_prediction.html 
MicroCosm: http://www.ebi.ac.uk/enright-srv/microcosm/cgi-bin/targets/v5/search.pl 
TargetScanHuman: http://www.targetscan.org/ 
miRanda: http://www.microrna.org/microrna/home.do 
miRDB: http://mirdb.org/miRDB/ 
PicTar: http://pictar.mdc-berlin.de/ 
Human Autophagy Database (HAD): http://autophagy.lu/ [185] 
 
Statistical Analyses 
Statistics were generated using the Student two tail t-test using Prism Graphpad. 
Representation of p values is as follows: p>0.05 (ns), p<0.05 (*), p<0.01 (**), p<0.001(***), 
p<0.0001(****). The number of replicates performed for every experiment is indicated in the 
figure legend of the respective experiment.  
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Chapter 3 
 
EVI1 Splice Variants Modulate Epithelial Mesenchymal Transition in Ovarian and Breast 
Cancer Cells  
    
Introduction      
 MDS1 and EVI1 complex locus (MECOM), located at the 3q chromosomal region 
(3q26.2) is amplified at the DNA level in serous EOC [2]. The DNA copy number increase at this 
locus in this subtype of ovarian cancer is associated with increased MDS1, EVI1, and 
MDS1/EVI1 splice transcripts and protein [2]. Increased EVI1 transcripts are linked to worsened 
patient outcome [2]. In contrast, increased MDS1/EVI1 transcripts are associated with good 
patient outcome [2], suggesting that these transcript variants may have opposing functions. A 
study conducted by our laboratory identified novel splice forms of EVI1 (using primers targeting 
the start and stop codons of MDS and EVI1) from normal epithelial ovarian and breast cells, 
ovarian cancer cell lines, and stage III/IV serous EOC specimens [14]. The major novel splice 
forms that were identified included EVI1Del190-515 and EVI1Del427-515 along with some rarer variants 
[14]. The EVI1Del190-515 splice variant (identical to the EVI1s or Del324 form earlier described  in 
Chapter 1) likely arises as a result of splicing between the donor splice site at the end of exon 6 
and a cryptic acceptor splice site within exon 7. The EVI1Del427-515 splice form is generated by a 
splicing event from an internal donor and acceptor site within exon 7 [14]. The EVI1Del190-515 form 
exhibited increased localization to PML nuclear bodies and a marked loss of transcriptional 
repressor activity with the TGF-mediated plasminogen activator inhibitor-1 (PAI-1) and 
activator protein-1 (AP-1) promoters relative to WT EVI1 and EVI1Del427-515 [14]. Further 
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investigation is necessary to elucidate the function of EVI1 and its splice variants in ovarian 
cancer biology.      
Previous reports described the contribution of EVI1 in mouse development and 
embryogenesis [186]. In addition, the C.elegans EVI1 homolog, egl-43, is reported to be 
involved in migratory and invasion events important in nematode development [187] [188]. 
Specifically, egl-43 induces breakdown of the basement membrane thereby promoting cell 
invasion. This event is mediated by the AP-1 (activator protein-1) pathway [189] which is also 
associated with the metastatic phenotype of solid tumors; AP-1 is a heterodimer comprised of c-
FOS and c-JUN [187]. EVI1 binds directly to the promoters of both AP-1 and c-FOS leading to 
cellular regulation of proliferation, cell adhesion, and colony formation [190]. It is presently 
unknown whether EVI1 splice forms regulate expression of genes involved in altering EMT, an 
important hallmark of cancer. Herein, we assessed whether EVI1 splice variants could regulate 
expression of molecules involved in EMT. We addressed this question using both ovarian and 
breast cancer cells since the molecular characteristics (amplification of 3q26.2 and high level 
EVI1 expression) of both of these cancer types are very similar [53]. In this chapter, we 
demonstrate that knockdown of certain EVI1 splice variants increases the expression of 
epithelial cell markers while inhibiting the cellular migratory potential of these two cancer cell 
types. 
 
Results 
 
siRNA targeting the splice junction between exon 2 of MDS1 to exon 2 of EVI1 elevates claudin-
1 protein 
In order to determine whether EVI1 splice variants modulate EMT, we decreased the 
protein expression of EVI1 splice forms using a siRNA knockdown strategy followed by an 
assessment of the protein expression of specific epithelial and mesenchymal markers in the 
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ovarian HEY and breast MDA-MB-231 cancer cell lines. Sequences for designing siRNA 
targeting specific splice variants were developed and validated by Jazaeri and colleagues [3]. 
As shown in Figure 7A and 7B, siRNA which targets exon 14 of WT EVI1 (siB) reduced WT 
EVI1, MDS1/EVI1, and the EVI1Del190-515 protein. siRNA which targets exon 6-7 junction (si2Kb) 
reduced EVI1Del190-515 protein. siRNA which targets exon 7 (si04) reduced MDS1/EVI1 protein. 
siRNA targeting the splice junction between exon 2 of MDS1 to exon 2 of EVI1 (siME) reduced 
both MDS1/EVI1 and the EVI1Del190-515 protein. Following knockdown in the two cancer cell lines 
using the above-described siRNA, we collected protein lysates and performed western analyses 
in these cell lines.    
Figure 7: Specific regions on the EVI1 splice variants targeted by the tested 
siRNA constructs  
 
(A) Schematic representation of EVI1 splice variants and the exonic regions targeted by 
the different siRNA constructs [3]. (B) The exact nucleotide position targeted by EVI1 
siRNA knockdown constructs are indicated in a tabular format [3]. (*Figure created by 
Punashi Dutta) 
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As shown in Figure 8A and 9A, we first ascertained successful knockdown of the 
different splice variants. We then measured protein expression of claudin-1, an epithelial marker 
whose gene is located at 3q28 (close to the 3q26.2 region where EVI1 is amplified in epithelial 
cancers). We observed a massive increase in the protein level of claudin-1 with siME in both 
HEY and MDA-MB-231 cells (Figure 8A and 9A). Additionally, we also assessed N-Cadherin, a 
mesenchymal cell marker, was decreased with siME in HEY cells. Densitometric analyses 
demonstrated that these changes were statistically significant (Figure 8B and 9B). In HEY cells, 
we also noted a reduction in SnoN protein with siB; SnoN (as described in Chapter 1) is also 
located at 3q26.2 (Figure 8A).  
Figure 8: Knockdown of EVI1 splice variants via siRNAs in HEY cells modulate protein 
levels of EMT markers 
 
(A) HEY cells were transfected with mock, control, siB, si2Kb, si04, and siME. Protein lysates 
were collected 48 hours post the second round of transfection. Samples were run on 8 or 12% 
SDS-PAGE gel and analyzed using the indicated antibodies. Western results shown above the 
dotted line are from samples run on 8% gel. Western results shown above the dotted line are 
from the same samples run on 12% gel. The data shown is representative of three different 
experiments. (B) Densitometric analyses performed on the western blotting results (presented in 
A) for N-Cadherin and claudin-1 protein levels in control or siME transfected HEY cells are 
presented in a graphical format along with p-values.  
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siRNA targeting the splice junction between exon 2 of MDS1 to exon 2 of EVI1 alters the RNA 
expression of key EMT markers  
Since we noticed changes in the protein levels of claudin-1 and N-Cadherin (markers of 
epithelial and mesenchymal phenotype, respectively), we next examined transcript level 
changes in these and other EMT markers via real-time PCR analyses. Consistent with the 
protein changes, the mRNA levels of claudin-1 were increased in both HEY and MDA-MB-231 
cells with siME. In contrast, siB reduced claudin-1 mRNA levels (Figure 10A and 10B).  
We next tested the effect of the above described siRNA (siB, siME) on other EMT 
markers including snail, slug, and twist (which all transcriptionally repress the expression of E-
Figure 9: Knockdown of EVI1 splice variants via siRNAs in MDA-MB-231 cells modulate 
protein levels of EMT markers 
 
(A) MDA-MB-231 cells were transfected with mock, control, siB, si2Kb, si04, and siME. Protein 
lysates were collected 48 hours post the second round of transfection. Samples were run on 8 
or 12% SDS-PAGE gel and analyzed using the indicated antibodies. Western results shown 
above the dotted line are from samples run on 8% gel. Western results shown above the dotted 
line are from the same samples run on 12% gel. The data shown is representative of three 
different experiments. (B) Densitometric analyses performed on the western blotting results 
(presented in A) for claudin-1 protein levels in control or siME transfected MDA-MB-231 cells 
are presented in a graphical format along with p-values.  
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Cadherin (an epithelial cell marker [191])) [192] [193, 194] [195]. We also included ZEB1/2 in 
our investigation since these proteins transcriptionally repress E-Cadherin expression [156, 
196]. Upon cellular treatment with siME, we observed reduced mRNA transcripts for twist, snail, 
and ZEB-1 in HEY cells and an increase in E-Cadherin in the MDA-MB-231 cells. Knockdown 
with siB increased slug and decreased claudin-1 levels in HEY cells also in addition to reducing 
E-Cadherin levels in MDA-MB-231 cells (Figure 10A and 10B). These results demonstrate that  
Figure 10: Knockdown of EVI1 splice variants via siRNAs in HEY and MDA-MB-231 
cells modulate mRNA expression of EMT markers (*Continued on next page) 
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knockdown with siRNA targeted towards the splice junction between exon 2 of MDS1 to exon 2 
of EVI1 (siME) led to increase in epithelial markers as opposed to siRNA targeting exon 14 of 
EVI1 (siB), which caused an increase in mesenchymal markers.   
 
Figure 10: Knockdown of EVI1 splice variants via siRNAs in HEY and MDA-MB-231 
cells modulate mRNA expression of EMT markers 
 
(A) RNA was isolated from HEY cells transfected with control, siB, or siME and real-time PCR 
analysis was performed for claudin-1, twist, snail, slug, ZEB-1, ZEB-2, and N-Cadherin. The 
correlative method was used for the real-time PCR analysis and -actin was used as the 
endogenous control. The data shown is compiled from three different experiments. (B) RNA 
was isolated from MDA-MB-231 cells transfected with control, siB, or siME and real-time PCR 
analysis was performed for claudin-1, twist, snail, slug, ZEB-1, ZEB-2, and N-Cadherin. The 
correlative method was used for the real-time PCR analysis and -actin was used as the 
endogenous control. The data shown is compiled from three different experiments. 
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siRNA targeting the splice junction between exon 2 of MDS1 to exon 2 of EVI1 reduces the 
migratory potential of HEY and MDA-MB-231 cells 
Since we observed an increase in claudin-1 and other EMT markers with siME and 
changes in EMT markers can alter migration [6], we performed a directional migration assay 
using the Boyden chamber using siME in HEY and MDA-MB-231 cancer cells. Since we 
observed an increase in epithelial markers upon siRNA knockdown targeting the splice junction 
between exon 2 of MDS1 to exon 2 of EVI1 (siME), we utilized this siRNA for this assay. HEY 
and MDA-MB-231 cells were transfected with non-targeting control or siME and the assay was 
conducted as described in Chapter 2.   
Figure 11: Effect of knockdown of EVI1 splice variants on the migratory potential of 
HEY and MDA-MB-231 cells 
 
Control or siME transfected HEY or MDA-MB-231 cells were re-seeded at 25,000 cells/well 
into 24 well plate inserts. Directional migration assay was performed and cells were 
stained using crystal violet dye, following which images were captured using a bright field 
light microscope. Representative images are presented along with quantitative analyses in 
a graphical format with p-values. The data shown are compiled from two different 
experiments. 
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As indicated in Figure 11, we observed a significant reduction in the cellular migratory 
potential in both HEY and MDA-MB-231 cells transfected with siME, compared to control 
transfected cells. These findings indicate that EVI1 splice variants alter cellular migration of HEY 
and MDA-MB-231 cancer cells.    
 
Specific EVI1 splice variants modulate claudin-1 promoter activity    
EVI1 is a transcriptional regulator and has the ability to bind DNA sequences via its Zn 
finger domains [197], thus regulating gene expression of a variety of genes (as mentioned in 
Chapter 1). As shown in Figures 8-10, siME increased mRNA and protein levels of claudin-1. To 
determine whether EVI1 splice variants can alter claudin-1 promoter activity, we used OVCAR8 
cells stably overexpressing specific EVI1 splice variants (WT EVI1, EVI1Del190-515, and EVI1Del427-
515). OVCAR8 cells have a deletion at the EVI1 chromosomal locus and therefore served as an 
appropriate model for overexpression studies [14].  
Figure 12: Effect of knockdown of EVI1 splice variants on the promoter activity of 
claudin-1 
 
OVCAR8 retroviral stable cells overexpressing control, WT EVI1, EVI1Del190-515, or EVI1Del427-515 
forms were transfected with pGL3 claudin-1 promoter plasmid. Luminescence was analyzed 
and data presented as a graph along with p-values. The data shown are compiled from two 
different experiments. 
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Luciferase-based reporter assay using pGL3 claudin-1 promoter construct was 
performed by transfecting this construct in the OVCAR8 overexpression cell lines. The results 
indicated a significant reduction in the relative light units with overexpression of WT EVI1 and 
EVI1Del427-515 form, but not with overexpression of the EVI1Del190-515 form, as compared to control 
transfected cells (Figure 12). These findings suggest that WT EVI1 and/or EVI1Del427-515 may 
bind to claudin-1 promoter to regulate its activity and thus modulate claudin-1 expression. 
 
siRNA targeting the splice junction between exon 2 of MDS1 to exon 2 of EVI1 does not alter 
the expression levels of the miR-200 family of miRNAs 
miRNAs affect multiple cellular processes, including gene regulatory networks involved 
in EMT [198]. With respect to EMT, the miR-200 family are well-described to be important 
regulators of this cellular process [199]. The miR-200 family of miRNAs is down-regulated 
during EMT [156]; overexpression of these miRNAs induce E-Cadherin expression, silence 
ZEB1/2 expression [17], enhance epithelial cell phenotype, and inhibit cellular motility [156]. 
Since EVI1 can regulate expression of specific miRNAs such as miR-143 [200], miR-124 [201], 
miR-96 [202], and miR-449A [203], we assessed whether the miR-200 family may be regulated 
via EVI1 splice variants. For this purpose, we transfected HEY and MDA-MB-231 cells with non-
targeting control siRNA or siME followed by miRNA isolation and quantification of miRNA-200 
family members (miR-200a, miR-200b, and miR-200c). As shown in Figure 13A and 13B, the 
knockdown of EVI1 splice variants did not alter the levels of these miR-200 family members. 
However, the present analysis was conducted only in 2 experimental replicates and variation 
was observed among the control transfected cells. 
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Reverse phase protein array (RPPA) analysis on cell lines overexpressing EVI1 splice variants 
In order to further assess cellular changes mediated by specific EVI1 forms, we stably 
overexpressed WT EVI1, EVI1Del190-515, and EVI1Del427-515 EGFP plasmids into appropriate 
ovarian cell lines. We selected the T29 normal immortalized ovarian and OVCAR8 ovarian 
cancer cells. Since T29 cells have low endogenous expression of EVI1, and the OVCAR8 cells 
have a deletion in the EVI1 locus, these cell lines served as a good overexpression model [14]. 
Two independent retroviral parental stable cell lines were generated for each of these cell lines. 
As shown in Figure 14, we validated the expression level of WT EVI1, EVI1Del190-515, and 
EVI1Del427-515 forms via western analysis using the cell signaling antibody towards the N terminal 
region of the protein. Additionally, we detected multiple other bands of lower molecular weights 
Figure 13: Effect of knockdown of EVI1 splice variants on the expression of miR-200a, 
miR-200b, and miR-200c 
 
HEY or MDA-MB-231 cells were transfected with control or siME and miRNA was isolated. 
Relative levels of miR-200a, miR-200b, and miR-200c were quantified by real-time PCR using 
the correlative method and RNU6B as the endogenous control. The data shown are derived 
from two different experiments. 
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which are likely to be proteolytic degradation products of the overexpressed forms or other 
splice variants of EVI1.  
 
We next assessed whether EVI1 splice variants (WT EVI1, EVI1Del190-515, and EVI1Del427-
515) altered the activation status and expression level of key signaling molecules in important 
signaling pathways (such as cell cycle, MAPK pathway, TGF pathway) via RPPA. This method 
assesses changes in protein expression using 154 validated antibodies (as described in 
Chapter 2) in a high-throughput manner. Since EVI1 negatively regulates the TGFpathway, an 
important signaling pathway dysregulated in ovarian cancer [204], we assessed the cellular 
response to EVI1 splice variant expression in the absence or presence of TGFtreatment. We 
Figure 14: Protein analyses of EVI1 splice forms in T29 and OVCAR8 cells 
 
T29 or OVCAR8 cells overexpressing control, WT EVI1, EVI1Del190-515, or EVI1Del427-515 cells 
(retroviral pools 1 and 2) were run on an 8% SDS-PAGE gel and western analyses performed 
for the indicated antibodies (EVI1 and GAPDH). 
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treated the overexpression cell lines with 50 pmol TGF for 5 minutes, 1 hour, 3 hours, 6 hours, 
and 24 hours. We noted a similarity in the expression of various mediators between the WT 
EVI1 and the EVI1Del427-515 form and between the control and the EVI1Del190-515 form, as shown in 
the heat map (Figure 15). A few targets assessed by RPPA appeared altered from the heat map 
presented in Figure 15 upon overexpression of WT EVI1 and EVI1Del427-515  including Cyclin E1.  
 
Cyclin E1 levels are altered upon TGFβ treatment in OVCAR8 ovarian cancer cells following 
overexpression of EVI1 splice variants   
Figure 15: Reverse phase protein array analysis (RPPA) in cells overexpressing EVI1 
splice forms 
 
Heat maps displaying the results obtained from RPPA analysis in T29 and OVCAR8 cells 
expressing EVI1 splice variants upon TGF treatment are shown.   
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Since RPPA analyses identified changes in Cyclin E1 protein following expression with 
WT EVI1 and EVI1Del427-515 form but not with the EVI1Del190-515 form, we next validated the change 
in cyclin E1 via western blotting. We observed an increase in the low molecular weight (LMW)  
 
forms of Cyclin E1. Cyclin E1 regulates the G1 phase of the cell cycle. Cyclin E1 and Cdk2 
together control the transition from the G1 to the S phase of the cell cycle [205]. Interestingly, 
LMW Cyclin E1 has been reported to stimulate the G1/S transition more efficiently as compared 
to the full length form [206]. In breast cancers, LMW Cyclin E1 is a potent predictor of breast 
cancer mortality, owing to their effect on genetic instability and cellular proliferation [207]. As a 
positive control, we used MCF7 cells overexpressing the full length and the LMW form of Cyclin 
Figure 16: Modulation of Cyclin E1 protein levels following EVI1 splice variants 
overexpression in OVCAR8 cells 
 
OVCAR8 cells overexpressing control, WT EVI1, EVI1Del190-515, or EVI1Del427-515 cells (retroviral 
pools 1 and 2) and MCF7 cells overexpressing full length and LMW Cyclin E1 forms were ran 
on an SDS-PAGE gel and western analysis was performed using the indicated antibodies. 
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E1, run together with the OVCAR8 overexpressing cells on the same SDS-PAGE gel (Figure 
16).  
To next assess the functional implications of the altered Cyclin E1 expression in 
OVCAR8 cells, we performed cell cycle analysis. As shown in Figure 17A and 17B, the WT 
EVI1 and the EVI1Del427-515 overexpressing OVCAR8 cells showed a subtle increase in the 
percentage of cells in the S phase and a decrease in percentage of cells in the G1 phase of the 
cell cycle. However, we did not identify any change in the percentage of cells in the different cell 
cycle phases with either the control or the EVI1Del190-515 form.   
  
Discussion   
Our findings reported in this chapter demonstrate that EVI1 splice variants modulate the 
mRNA and/or protein levels of specific EMT markers. Alterations in these EMT mediators using 
Figure 17: Cell cycle analysis following EVI1 splice variants overexpression in OVCAR8 
cells.  
 
(A) Graphical representation of cell cycle stages in OVCAR8 cells expressing EVI1 splice 
forms. The data shown is compiled from two different experiments. (B) Tabular representation 
of results presented in (A) are shown. 
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siME were associated with reduced migratory potential of HEY and MDA-MB-231 cancer cells. 
Our studies suggest that EVI1 splice variants elevate claudin-1 and reduce migration which may 
contribute to the pathophysiology of ovarian and breast cancers. We did not observe any 
change in the expression levels of miR-200 family with the siME knockdown. However, it is 
possible that the miRNAs are unable to bind to the 3’UTR of the respective genes due to the 
presence of RNA binding proteins such as HuR [208]. It would therefore be necessary to 
investigate the mechanism by which EVI1 variants may modulate miRNA:mRNA target binding 
affinity. Since our findings implicate a role of EVI1 splice variants in modulating EMT markers, it 
would be worthwhile to investigate and analyze the expression levels of EVI1 splice variants in 
patient specimens and their association to the expression of EMT markers.   
Of interest, we saw a significant increase in both protein and mRNA levels of claudin-1, 
an epithelial marker in both HEY and MDA-MB-231 cells upon knockdown of MDS1/EVI1 and 
EVI1Del190-515 form. Claudin-1 is located very close to the 3q26 region (where EVI1 is located), at 
3q28. Our group has previously demonstrated that SnoN/SkiL, located at 3q26.2, can regulate 
the expression of PLSCR1, a gene present in close proximity at 3q23 [157]. Therefore, genes 
located in close proximity to each are likely to regulate each other’s expression levels. Since 
EVI1 functions as a transcriptional regulator, EVI1 and/or its splice variants may regulate the 
expression of these EMT mediators by directly binding to the DNA sequence of these genes. 
We observed notable differences in the claudin-1 promoter activity upon overexpression with 
specific EVI1 splice variants. Interestingly, the WT EVI1 and EVI1Del427-515 form behaved similarly 
(both down-regulated the promoter activity of claudin-1) and in contrast to the EVI1Del190-515 form 
(which was similar to control) a trend also observed in the RPPA analysis. It is established that 
altered ratios of splice variants can modulate cellular responses [209]. These altered ratios 
rather than the reduction in a particular splice variant may be contributing to the observed 
changes in EMT and migratory potential. Moreover, the EVI1Del190-515 form showed altered 
nuclear localization and binding to interacting partners of WT EVI1 [14]. Therefore, we believe 
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that the EVI1Del190-515 splice form may be exhibiting a dominant-negative effect on the cellular 
functions of WT EVI1.    
It is presently unclear how EVI1 splicing events are regulated. Since a balance between 
expression levels of splice variants can elicit diverse cellular responses [209], it would be 
necessary to investigate the mechanism of EVI1 splicing. Several signaling pathways regulate 
splicing events by directly modulating SR (serine/arginine-rich) proteins which are major splicing 
factors [210]. Some of these signaling pathway mediators such as Ras and PI3K/AKT are 
dysregulated in ovarian cancers and thus may modulate the alternative splicing [211, 212]. 
Other factors that may regulate splicing are the presence of mutations; however, our research 
group did not identify any mutations upon sequencing EVI1 from serous EOC patient specimens 
[2]; however, there could be mutations deep within the introns, resulting in a cryptic 
acceptor/donor splice site.  
Our results suggest that EVI1 splice variants may behave differently from the WT EVI1 
and since the splice variants have altered exonic regions, their binding affinity to interacting 
partners is affected. Indeed, a study by Copeland and colleagues identified 78 EVI1 interacting 
partners via SILAC, and further validated 22 of these targets via co-immunoprecipation studies, 
followed by yeast-two-hybrid experiments witch validated five EVI1 binding partners [88].  In 
order to understand the functions of the splice variants in ovarian and breast cancers, it is 
necessary to determine differential binding of these to known EVI1 binding partners and further 
identify new binding partners and the implications in ovarian/breast cancer biology. Additionally, 
although EVI1 is a nuclear protein [78], whether EVI1 localizes to other subcellular regions is 
presently unknown. Since subcellular localization can affect protein function [213] it would be 
worthwhile to study this in detail. Our RPPA and western data indicated elevated protein levels 
of LMW Cyclin E1 in cells overexpressing WT EVI1 or EVI1Del427-515 form, which was consistent 
with an increase in cells in the S phase of the cell cycle. However, Cdk2 and Cyclin E1 kinase 
activity remained unaltered with the overexpression of the splice variants, therefore, it is 
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possible that the altered Cyclin E1 expression via the overexpression of splice variants in 
OVCAR8 cells is independent of the dysregulation in the cell cycle.      
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Chapter 4 
 
miR-494 Modulates SnoN/SkiL Expression and Cell Death Response upon As2O3 
Treatment in Ovarian Cancer Cells   
    
Introduction  
Serous EOC accounts for 70% of the deaths due to ovarian cancer, which is the fifth 
most common cause of mortality due to cancer in women in the United States [29]. As 
mentioned in Chapter 1, the high mortality rate in this cancer is due to the absence of early 
detection biomarkers and methods. Serous EOC exhibits amplification of genes at the 3q26 
chromosomal region, including MECOM [214] and SnoN/SkiL [215]. There is substantial 
evidence suggesting that aberrant genomic regions contribute to ovarian cancer biology [216, 
217]. Therefore, an in-depth understanding of the regulation of genes that are highly amplified 
and aberrantly expressed in epithelial EOC may aid in development of tools for early diagnosis 
and better therapeutic treatment strategies. SnoN/SkiL, located at the 3q26.2 locus is elevated 
in a variety of cancers (such as colorectal cancer, esophageal squamous cell cancer, and 
melanoma) at the DNA level in addition to being overexpressed at the mRNA and protein levels 
[1, 91, 99, 101, 218, 219]. SnoN negatively regulates the TGF pathway (a pathway 
dysregulated in ovarian cancer [220]), by binding Smads and inhibiting the transcription of TGF 
regulated genes [92]. However, SnoN can also bind to transcriptional inhibitors such as HDACs 
and inhibit the activity of Smads [94]. Interestingly, SnoN exhibits both pro- and anti-tumorigenic 
properties at different stages of malignant progression in epithelial cancers [101].   
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Previous studies from our group demonstrated that SnoN expression is elevated 
following treatment with chemotherapeutic drugs such as As2O3 in ovarian cancer cells [15]. 
As2O3, a chemotherapeutic agent that has been FDA approved for the treatment of acute 
promyelocytic leukemia (APL) [221] reduces cell proliferation in solid cancers including ovarian 
cancer [222-224]. This increase in SnoN levels was at the mRNA and protein levels; its levels 
were associated with increased LC3B-II (an autophagy marker) and the presence of double 
membrane autophagosomes assessed by TEM [15]. LC3 becomes conjugated with PE to form 
LC3-II and translocates from the cytosol to the autophagosome membrane, a hallmark event in 
the induction of autophagy [225]. Further, the induction of autophagic flux was demonstrated by 
EGFP-LC3 punctae formation and assessment of LC3-II protein levels upon the use of early 
and late stage autophagy inhibitors such as 3-methyladenine (3-MA) and bafilomycin A1 (BAF) 
[15]. Importantly, siRNA mediated knockdown of SnoN reduced LC3-II protein levels, decreased 
EGFP-LC3 punctae, and led to increased apoptosis by As2O3 treatment [15]. In a recent study, 
we demonstrated that SnoN induction is mediated by the activation of PI3K/AKT pathway upon 
As2O3 treatment [17]. As2O3-mediated increase in SnoN expression was antagonized by 
inhibitors of PI3K or by knockdown of PIK3CA [17]. However, the detailed mechanism 
underlying the induction of SnoN expression upon treatment with As2O3 is unclear and requires 
further investigation.    
Gene regulatory pathways mediated by miRNAs are critical in post-transcriptional 
regulation of gene expression [127]. miRNAs bind the target mRNA at the 3’UTR and inhibit 
gene expression via mRNA degradation or inhibition of translation [124]. However, it has 
recently been reported that miRNAs may bind to the 5’UTR [226] or coding region [227] within 
the mRNA target sequence. Interestingly, c-Ski (a homolog of SnoN/SkiL [228]) is a target of 
miR-155 in human melanoma cells; its down-regulation by miR-155 leads to reduced melanoma 
cell proliferation [19]. Additionally, miR-29a, miR-127, and miR-21 also target c-Ski in AML [20], 
glioblastoma [21], and rat vascular smooth muscle cells [22], respectively. Whether SnoN 
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expression is regulated by miRNAs is presently unknown. Our findings reported in this chapter 
demonstrate that miR-494 overexpression in HEY ovarian cancer cells reduces both mRNA and 
protein levels of SnoN. Of interest, we identified a perfect miR-494 binding site in the 3’-UTR 
region of SnoN via in silico analysis. Further, miR-494 sensitized HEY ovarian cancer cells to 
As2O3 treatment, increasing cell death due to apoptosis. Additionally, miR-494 reversed the 
formation of EGFP-LC3B punctae mediated by SnoN upon treatment with As2O3. Collectively, 
these findings implicate miR-494 in modulating drug-induced cell death response via reducing 
SnoN mRNA and protein levels.     
 
Results 
 
Bioinformatic analyses reveal miR-216b, miR-410, miR-494, and miR-495 putative binding sites 
in the 3’UTR of SnoN   
Figure 18: miR-494 modulates SnoN protein levels (*Continued on next page) 
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Since SnoN is a homolog of c-Ski, which is regulated via miRNAs in several cancer 
types [19-22], we investigated whether SnoN levels are modulated via the action of miRNAs. 
Therefore, in order to identify putative miRNA binding sites in the 3’UTR of SnoN, we conducted 
bioinformatics analyses using six different bioinformatics programs including Pictar, 
Geneocopoeia, Microcosm, miRDB, TargetScanHuman, and miRANDA. Four miRNAs (miR-
216b, miR-410, miR-494, and miR-495) were identified in four or more of these above stated 
bioinformatics programs to have potential binding regions in the 3’UTR of SnoN. A Venn 
diagram summarizing the results obtained from the in silico analysis is presented in Figure 18A.  
Figure 18: miR-494 modulates SnoN protein levels  
 
(A) A Venn diagram is presented which summarizes the top hits from miRNA analysis 
performed using six different bioinformatics programs (PicTar, Microcosm, miRANDA, 
TargetScanHuman, miRDB, and Genecopoeia) showing miRNA putative binding sites in the 3’-
UTR of SnoN/SkiL. (*Figure created by Dr. Nanjundan). (B) HEY cells expressing negative 
control miR, miR-216b, miR-410, miR-494 or miR-495 mimic (200 pmol) for 96 hours were 
treated with 25 µM As2O3 for 6 hours. Protein lysates were harvested and subjected to western 
analyses using the indicated antibodies. The data shown is representative of two different 
experiments. (C) Schematic representation of miR-494 binding sites in the SnoN 3’UTR. Green 
boxes indicate the binding region on the SnoN transcript. 
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In order to validate the results obtained from the bioinformatics study, we performed 
western blotting analysis to examine SnoN protein levels upon exogenous transfection of these 
miRNAs. For this purpose, we transfected HEY ovarian cancer cells with 200 pmol of the above 
mentioned miRNAs (presented as mimics) for 96 hours, a time point used in previous studies 
[229]. We performed this analysis with or without 6 hour As2O3 treatment, since SnoN levels are 
induced with As2O3 treatment at this time point in HEY cells [15]. As shown in Figure 18B, we 
identified a reduction in the protein levels of SnoN upon transfection with miR-494 mimic in the 
presence of As2O3 treatment, but not with the other miRNAs (miR-216b, miR-410, and miR-
495). A schematic of the 3’UTR of SnoN with the binding site for miR-494 is presented in Figure 
18C.  
     
 miR-494 modulates SnoN protein and mRNA expression 
To determine whether the reduction in SnoN protein with miR-494 mimic transfection 
(Figure 18B) was dependent on the duration of mimic transfection, we harvested protein lysates 
from HEY cells at 24, 48, 72, and 96 hours post-transfection with or without 6 hours As2O3 
treatment. As shown in the western blots presented in Figure 19A, protein levels of SnoN were 
down-regulated in a time-dependent fashion with a maximum reduction at 72 and 96 hours post-
mimic transfection with As2O3 treatment. We also assessed the levels of LC3B (an autophagic 
marker) in our western analysis since the induction of SnoN upon As2O3 treatment leads to an 
increase in LC3-II [15]. Interestingly, we observed a reduction in LC3B-II with miR-494 
transfection supporting a previous report by our group which demonstrated a reduction in LC3B-
II upon siRNA-mediated knockdown of SnoN [15]. Since the reduction in SnoN protein levels 
reached a peak at 96 hours post-transfection, we used this time point for further studies 
described in this chapter.          
The base-pairing complementarity between the miR-494 and the target mRNA sequence 
will determine the mechanism of gene repression via miRNAs [230]. miRNAs repress gene  
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Figure 19: miR-494 modulates SnoN mRNA expression 
 
(A) HEY cells expressing miR-494 or negative control miR mimic for 24 to 96 hours were 
treated with 25 µM As2O3 for 6 hours. Protein lysates were harvested and subjected to 
western analyses using the indicated antibodies. The data shown is representative of two 
different experiments. (B) HEY cells expressing miR-494 or negative control miR were 
treated with 25 µM As2O3 for 6 hours. Total RNA was isolated and used for real-time PCR. 
Relative RNA-fold changes are presented for SnoN. The data shown is derived from two 
different experiments. 
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expression via mRNA degradation (perfect complementarity base pairing between miRNA and 
mRNA) or translational inhibition (imperfect complementarity base pairing between miRNA and 
mRNA) [230]. Since the 3’UTR of SnoN harbors a perfect complementary site for miR-494, we 
next examined whether miR-494 affected the mRNA expression of SnoN, in addition to protein 
level changes. Therefore, we transfected HEY cells with miR-494 mimic in the presence or 
absence of As2O3 treatment for 6 hours and isolated mRNA. Real-time PCR analysis revealed a 
significant reduction in SnoN mRNA levels (as shown in Figure 19B) both in the presence and 
absence of As2O3 treatment. 
 
miR-494 leads to the formation of diffused EGFP-LC3B expression upon As2O3 treatment     
As shown in Figure 19A, miR-494 overexpression reduced LC3B-II protein levels. Our 
group has previously shown that As2O3 treatment led to increase in LC3B-II protein levels which 
Figure 20: Pattern of EGFP-LC3B expression in miR-494 overexpressing cells in the 
presence of As2O3 treatment  
 
(A) HEY cells expressing miR-494 or negative control miR were transfected with pEGFP-LC3. At 
72 hours post-transfection, cells were treated with 10 M As2O3 for 18 hours. Representative 
immunofluorescence images are shown; EGFP-LC3 punctae were quantified by counting the 
number of cells positive for EGFP-LC3 punctae. The data shown is representative of two different 
experiments. (B) The graph presents the results from (A) as the percentage of cells with positive 
GFP-punctae. The data shown is compiled from two different experiments. 
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were associated with the formation of distinct EGFP-LC3B punctae [15]. Therefore, we next 
investigated whether miR-494 can alter the formation of EGFP-LC3B punctae upon treatment 
with As2O3, mediated by SnoN. For this purpose, we transfected HEY cells with control or miR-
494 mimic as well as EGFP-LC3B plasmid in the presence of As2O3. As expected, we observed 
an increase in distinct EGFP-LC3 punctae with drug treatment in the control cells. However, 
miR-494 overexpression altered the LC3B pattern to a diffuse expression in the presence of 
As2O3 (Figure 20A). Indeed, we noted a significant reduction in the percentage of GFP positive 
punctae with miR-494 expression (Figure 20B).   
 
miR-494 sensitizes the cellular response of HEY ovarian cancer cells to As2O3 treatment     
Since As2O3 treatment reduces HEY cell viability [15], we next assessed whether miR-
494 could modulate this cellular response. Thus, we transfected these cells with miR-494 mimic 
in the absence or presence of As2O3 for 18 hours (a time point previously shown to induce cells 
death in these cells [15]). 
Figure 21: miR-494 sensitizes HEY ovarian cancer cells to As2O3 treatment (*Continued on 
next page) 
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Figure 21: miR-494 sensitizes HEY ovarian cancer cells to As2O3 treatment 
 
(A) HEY cells expressing miR-494 or negative control miR were assessed for changes in cell 
viability by crystal violet staining, both in the presence and absence of 25 M As2O3 for 18 hours. 
The data shown is compiled from two different experiments. (B) Light microscope images of HEY 
cells expressing miR-494 or negative control miR in the presence or absence of 25µM As2O3 for 18 
hours. (C) HEY cells expressing miR-494 or negative control miR mimic for 96 hours were treated 
with 25µM As2O3 for 18 hours. Protein lysates were harvested and subjected to western analyses 
using the indicated antibodies. The data shown is representative of three different experiments. (D) 
HEY cells expressing miR-494 or negative control miR were treated with 25 M As2O3 for 18 hours. 
Ninety-six hours post-transfection, both adherent and floating cells were collected and processed, 
as indicated in the materials. Cells were then stained with annexin V-FITC and propidium Iodide 
(PI) followed by flow cytometry. Raw data plots and light microscopic images are presented. The 
data shown is representative of two different experiments. (E) The percentage of viable, early 
apoptotic, and late apoptotic/necrotic cells from (D) is presented in a graphical format. The data 
shown is compiled from two different experiments. 
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We performed cell viability analysis using crystal violet staining and observed that miR-494 
decreased cellular survival both with and without drug treatment. (Figure 21A). Interestingly, the 
morphology of the cells was altered dramatically upon miR-494 expression; in particular, the 
cells exhibited increased cytoplasmic area with a phenotype similar to that observed in 
senescent cells (Figure 21B).  As mentioned above, our group previously demonstrated that the 
inhibition of SnoN expression (via siRNA-mediated knockdown) in HEY ovarian cancer cells 
upon As2O3 treatment increases cell death via apoptosis [15]. Therefore, in order to determine 
whether the reduction in SnoN levels by miR-494 mimic increases cell death by apoptosis in 
HEY cells, we performed western blotting analysis to assess the levels of cleaved PARP (a 
marker for apoptotic cell death [231]), in HEY cells following miR-494 mimic transfection and 
As2O3 treatment. Indeed, miR-494 overexpression elevated cleaved PARP levels in response to 
As2O3 treatment (Figure 21C). A reduction in both SnoN and LC3B was also observed, as 
reported earlier (Figure 19A).  
Furthermore, in order to validate whether apoptosis was involved in the cell death 
mechanism, we conducted annexin V/PI staining in these cells followed by flow cytometry. The 
apoptotic response with miR-494 expression (early and late apoptotic cell populations) was 
significantly increased with miR-494 mimic in the presence of As2O3 (Figure 21D and 21E), 
demonstrating that miR-494 sensitized the cells to As2O3-mediated apoptotic cell death 
response.     
  
Discussion 
As2O3 modulates SnoN expression and consequent autophagic response in ovarian 
cancer cells [15]. In this chapter, we demonstrate that miR-494 mimic overexpression 
antagonizes SnoN induction in the presence of As2O3 and sensitizes the cells, increasing the 
cell death response via apoptosis. We also show that miR-494 overexpression leads to reduced 
LC3-II protein levels and diffused EGFP-LC3 punctae. Additional experiments will need to be 
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performed in order to determine whether this reduction in LC3-II and altered EGFP-LC3 punctae 
is also associated with modulation in autophagic flux. It would also be necessary to validate the 
outcomes observed upon miR-494 mimic overexpression by using miR-494 antagomir in order 
to determine whether endogenous miR-494 activity is abrogated with the anatgomir in the 
presence of As2O3. Although we attempted to determine whether the miR-494 effects could be 
reversed using Ago2 (the slicer activity of which is required for the establishment of RNA 
inducing silencing complex (RISC) [232]) siRNA, the results obtained were unexpected. We did 
not observe reduction in SnoN protein level with miR-494 in the presence of control siRNA 
(results not shown). Since the combination of control siRNA and miR-494 mimic did not elicit the 
response (reduction in SnoN protein) as observed by the transfection of miR-494 mimic alone, it 
was difficult to interpret the results. Other experimental technical modifications need to be 
implemented to study this further.    
Several reports have identified a subset of miRNAs that are altered upon As2O3 
treatment [233, 234]. We attempted to measure endogenous miR-494 levels upon treatment 
with As2O3, in order to determine whether the levels of miR-494 are altered.  However, due to 
technical shortcomings associated with real-time PCR quantification analysis, we were unable 
to derive conclusions. Additionally, similar to our findings, miR-494 appears to be involved in 
cinobufacin [139] and fluorouracil [235] (anti-cancer agents) mediated cell death. We have 
previously reported that SnoN is induced upon drug treatment via the activation of the 
EGFR/PI3K/AKT pathway [17]. Interestingly, several studies have indicated that miR-494 is 
involved in the modulation of the PI3K/AKT pathway, thereby affecting cell proliferation and 
apoptosis [236, 237]. However, the detailed mechanism by which SnoN is induced upon As2O3 
treatment and whether cross-talk occurs between EGFR pathway and miR-494 is involved in 
this mechanism remains to be identified.    
miRNA expression patterns are dysregulated in a variety of cancer types [238]. Analysis 
of miRNA expression profiles may provide better insight into the dysregulated molecular 
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mechanisms that are critical in tumorigenesis [238]. We have identified miRNAs that may target 
the 3’-UTR of SnoN (Figure 18A). Several of these miRNAs are associated with ovarian cancer 
biology including miR-497 [239-242], miR-655 [240], miR-424 [243, 244] and miR-410 [245]. In 
this regard, it would be interesting to assess their contribution in altering SnoN expression. 
Interestingly, Cheng and colleagues demonstrated a ~2-fold reduction in miR-494 expression in 
primary ovarian tumors relative to the normal ovary [134]. More recently, it was noted that miR-
494 was markedly down-regulated in ovarian cancer cells (SKOV3, KF, KFr-, Tx, TUOS3, and 
TUOS-4) relative to normal ovarian cells (IOSC397 and IOSC386) [246]. Further, several in 
silico approaches have been applied to identify miRNAs that are altered in ovarian cancer 
development that could potentially regulate expression of mediators of the autophagic pathway 
[247]; additional experimental work is needed to validate these observations. In this regard,	 it 
would be worthwhile to examine miR-494 expression levels in serous EOC patient specimens 
compared to normal ovarian cells and correlate these to the presence/absence of autophagic 
markers, since SnoN modulates the autophagic pathway induced upon As2O3 treatment in 
ovarian cancer cells [15]. miR-494 has been reported to suppress cell proliferation in prostate 
[137], lung [248] and gastric cancers [24, 139, 249]. Similar to our studies in ovarian cancer 
cells, miR-494 also induces cell death responses, including apoptosis [250] in a variety of other 
cancers such as glioblastoma [251] and small cell lung cancers [252].  
miR-494 is located at the 14q chromosomal region (14q32) [253]. A study conducted by 
Bandera and colleagues to determine loss of heterozygosity at the 14q arm in ovarian cancer 
demonstrated 14q32.1-14q32.2 to be one of the regions deleted at this arm [115]. Strikingly, 
another study also indicated the deletion at 14q32.1-14q32.2 to have a possible contribution in 
the progression of bladder cancer [254]. More importantly, this 14q region is also frequently 
deleted in renal cancer [23]. This observation is supported by the TCGA research network [43]. 
The 14q32 chromosomal region harbors a 54 miRNA cluster, which includes miR-494 [253]. 
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Therefore, in the next chapter (Chapter 5) we attempted to study the functional consequences 
of miR-494 expression in renal cancer cells.     
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Chapter 5  
 
miR-494 Modulates Cell Survival and Induces Lipid Droplet Formation in Renal Cancer 
Cells 
  
Introduction       
The loss of heterozygosity associated with the 14q chromosomal region has been 
reported in several cancers such as renal [23] [43], ovarian [115], bladder [254], colorectal [255], 
endometrial [256], and neuroblastoma [257]. As discussed in Chapter 4, the 14q32 
chromosomal region, in particular contains the DLK1-DIO3 genomic cluster. This cluster harbors 
a set of 54 miRNAs (among other important imprinted genes) that are dysregulated in various 
solid and blood cancers, including renal cancer (Figure 22) [253]. miRNAs are a class of non-
coding RNA molecules that do not translate into a functional protein [258]. Nevertheless, they 
are involved in a wide variety of cellular processes and control gene expression patterns, which 
are critical in disease progression, including cancer [259]. miRNAs are located in regions of the 
genomes that are aberrant in cancers [260]; further, miRNA expression patterns are important 
diagnostic indicators of patient survival [261, 262]. miRNAs exert their enzymatic activity by 
direct binding to target mRNAs and to inhibit gene expression via translational inhibition and/or 
mRNA degradation [259] (Chapter 1, Figure 4). However, recent reports have indicated that 
miRNAs may also positively regulate gene expression [128-130].   
In Chapter 4, we demonstrated that miR-494 mediates cell death response induced 
upon drug treatment in HEY ovarian cancer cells. Interestingly, miR-494 is located at 
chr14:101,495,971-chr14:101,496,051, within the 14q32 cluster [131]. The functional effect of 
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miR-494 has been investigated in a number of cancer types, implicating it in a variety of cancer-
related responses such as EMT [263], senescence [135, 264], cell cycle arrest [25], and 
apoptosis [24]. Interestingly, miR-494 is associated with both oncogenic and tumor suppressive  
functions. For example, miR-494 targets PTEN, inhibiting apoptosis [251], down-regulates pro-
apoptotic BIM in non-small cell lung carcinoma [142], and enhances glioma cell invasion by 
stabilizing EGFR [237]. Additionally, miR-494 targets and inhibits the gene expression of several 
invasion-suppressing miRNAs in hepatocellular cancer [146] and elicits oncogenic functions in 
colorectal cancer [145]. On the contrary, the tumor suppressive properties of miR-494 include 
attenuation of cell proliferation and induction of senescence in lung cancer cells [248], induction 
Figure 22: The DLK1-DIO3 genomic cluster harbors a set of 54 miRNAs 
 
Schematic representation of the DLK1-DIO3 miRNA cluster at the 14q32 chromosomal locus, 
spanning ch14:100726865 to ch14:101563452. (*Figure created by Punashi Dutta) 
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of cell cycle arrest in cholangiocarcinoma cells [25], and targeting c-KIT [24] and c-myc [249] to 
impede gastrointestinal tumor proliferation. Further, miR-494 suppresses breast [265], cervical, 
and oral [136] cancer progression. In addition, miR-494 also elicits functional responses in other 
diseases like neurodegeneration [266] and cystic fibrosis [267, 268]. Collectively, these studies 
indicate that a particular miRNA elicits different functional activity depending on the disease 
type. Table 1 presented in Chapter 1 summarizes all the targets of miR-494 that have been 
identified thus far. Although miR-494 targets and functions have been identified in other cancer 
cell types, nothing is yet known about miR-494 in renal cancer biology. Thus, we hypothesize 
that miR-494 expression reduces renal cell survival. 
In this chapter, we attempt to elucidate the functional outcomes elicited by the 
exogenous expression of miR-494 mimic in renal cells. We demonstrate that miR-494 reduces 
renal cancer cell survival, a response accompanied by increased LC3B (both mRNA and 
protein), cleaved PARP, and apoptosis. We identified LC3B as a novel possible miR-494 target 
via luciferase assay. Expression of miR-494 in 769-P renal cancer cells led to increased lipid 
droplets (LDs) and reduced total cellular cholesterol amounts. This accumulation in LDs was 
mediated via LC3B. miR-494 expressing cells exhibit disorganized mitochondrial structural 
pattern, which is associated with reduced PINK1 protein levels and altered Drp1 subcellular 
localization. 
  
Results  
miR-494 modulates the protein levels of LC3B and cleaved PARP in normal and renal cancer 
cells   
Since miR-494 is located within the frequently deleted 14q region [23] [45] and 
considering previously published reports of the cell death and tumor suppressive responses 
elicited by miR-494 in cancers (as stated above), we assessed the functional outcomes upon 
miR-494 mimic transfection in renal cells. We transfected immortalized normal kidney tubule 
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HK-2 cells [269] as well as three renal cancer cell lines (769-P, 786-O, and A-498) with negative 
control or miR-494 mimic and examined changes in cellular morphology ninety-six hours post 
miR-494 transfection (a similar time point used for miRNA studies in Chapter 4). Light 
microscopic images showed a noticeable reduction in cell density and appearance of large 
cytoplasmic vacuoles in HK-2 and 769-P cells expressing miR-494 (Figure 23A). No distinct 
morphological changes were observed in A-498 cells, although 786-O cells demonstrated a 
disorganized pattern. Since autophagy and apoptotic pathways mediate cellular death 
responses [270], we next tested the protein levels of LC3B (an autophagic marker) and cleaved 
PARP (an apoptotic marker) in miR-494 expressing cells as compared to control.  
 
Figure 23: miR-494 modulates cell death in renal cancer cells (*Continued on next 
page) 
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Figure 23: miR-494 modulates cell death in renal cancer cells 
 
(A) Bright field light microscopic images of HK-2, 769-P, 786-O, and A-498 cells captured 96 
hours post-transfection with negative control miR or miR-494 mimic (200 pmol). (B) HK-2, 769-
P, 786-O, and A498 cells were transfected with negative control or miR-494 mimic. Protein 
lysates were collected 96 hours post-transfection and samples run on a 10% SDS-PAGE gel. 
Western blotting analyses were performed using the specified antibodies as shown. The data 
shown is representative of three different experiments. (C) HK-2, 769-P, 786-O, and A498 cells 
were treated as (A). Ninety-six hours post-transfection, both adherent and floating cells were 
collected and processed, as indicated in the materials and methods section. Cells were further 
stained with annexin V-FITC and PI followed by flow cytometric analysis. Raw data plots are and 
the percentage of viable, early apoptotic, and late apoptotic/necrotic cells are presented. The 
data shown is compiled from three different experiments. 
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As shown in Figure 23B, we observed an increase in LC3B in HK-2, 769-P, and A-498 
cells. Cleaved PARP levels increased with miR-494 expression in HK-2, 769-P, and 786-O 
cells. Further, in order to determine whether cell death response was mediated by apoptosis, we 
performed annexin V/PI staining in these cells. miR-494 expression induced a significant 
Figure 24: miR-494 reduces 769-P viability and colony forming ability 
 
(A) 769-P cells expressing miR-494 or control miR were re-seeded in 96 well plate 24 hour post-
mimic transfection. These cell were assessed for changes in cell viability by crystal violet 
staining, 96 hours post-mimic transfection. The data shown is derived from two different 
experiments.  (B) 769-P cells expressing miR-494 or control miR, grown for 2 weeks at low 
density (5,000 cells initial seeding/well), were stained with crystal violet. The data shown is 
representative of two different experiments. (C) Control or miR-494 mimic transfected 769-P 
cells were processed for miRNA isolation 96 hours post-transfection. miR-494 levels were 
quantified by real-time PCR using the correlative method and RNUB6 was used as the 
endogenous control. Cycle threshold (CT) value and RNA-fold changes are presented. The data 
shown is compiled from three different experiments.
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increase in late apoptotic cell numbers in HK-2, 769-P, and 786-O cells (Figure 23C). Since we  
observed changes in both LC3B and cleaved PARP protein levels with miR-494 expression in 
769-P cells, we also tested changes in cell viability using crystal violet staining in these cells. As 
indicated in Figure 24A, we noticed a significant decrease in cell viability with miR-494. Next, we  
performed a colony formation assay which assesses the ability of cells to form colonies in 
culture. For this purpose, miR-494 mimic transfected 769-P cells were plated at a low density of 
5000 cells/well of a six-well plate. After carefully monitoring the cells over a period of 2 weeks, 
we stained them with crystal violet. We noticed an attenuation in the colony formation ability of 
the cells transfected with the miR-494 mimic, as depicted in the Figure 24B. We also quantified 
miR-494 levels upon mimic transfection via real-time PCR analysis and found these to be within 
the physiological limit of endogenously expressed miRNAs [271] (Figure 24C). These 
experiments suggest that miR-494 elicits tumor suppressive responses in renal cells.     
 
miR-494 antagomir and Ago2 siRNA-mediated knockdown reverse the induction of LC3B-I/II 
and cleaved PARP protein levels in 769-P renal cancer cells upon miR-494 mimic transfection     
In order to ensure that the functional response elicited by miR-494 (increase in LC3B 
and cleaved PARP protein levels) occurred via the miRNA pathway, we transfected 769-P cells 
with different miR-494 mimic/antagomir combinations. These included (1) control mimic, (2) 
miR-494 mimic, (3) control antagomir, (4) miR-494 antagomir, (5) control mimic and control 
antagomir, (6) control mimic and miR-494 antagomir, (7) control antagomir and miR-494 mimic, 
and (8) miR-494 mimic and miR-494 antagomir. Light microscopy images obtained 96 hours 
post-transfection indicated that transfection with miR-494 antagomir reversed the effect on cell  
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Figure 25: Validation of miR-494-mediated cellular responses 
 
(A) Light microscopic images of 769-P cells transfected with negative control or miR-494 
mimic/antagomir at 96 hours post-transfection is presented. (B) 769-P cells were transfected as 
stated above in (A). Protein lysates were collected 96 hours post-transfection and samples run on 
a 10% SDS-PAGE gel. Western blotting analyses were performed using the specified antibodies 
as shown. The data shown is representative of three different experiments. (C) Control or Ago2 
siRNA transfected 769-P cells were transfected with negative control or miR-494 mimic. Light 
microscope images were captured at 96 hours post-transfection and representative images are 
presented. (D) 769-P cells were treated as described above in (C). Protein lysates were collected 
96 hours post-transfection and samples run on a 10% SDS-PAGE gel. Western blotting analyses 
were performed using the specified antibodies as shown. The data shown is representative of 
three different experiments.   
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density that was observed with miR-494 mimic (Figure 25A). The miR-494 antagomir also 
inhibited the increase in LC3B and cleaved PARP protein levels observed with miR-494 mimic 
expression (Figure 25B). In addition, we also performed siRNA-mediated knockdown of Ago2. 
The miR-494 mimic (that we have utilized for overexpressing miR-494 for our studies herein) is 
the mature miRNA form which requires the activity of endogenous Ago2 in order to bind to the 
target mRNA. Therefore, in order to determine whether knockdown of endogenous Ago2 can 
affect the activity of the mimic, we performed siRNA-mediated knockdown of Ago2 and then 
transfected the cells with the miR-494 mimic. As shown in Figure 25C and 25D, we did not 
observe changes in LC3B and cleaved PARP upon miR-494 mimic transfection in the presence 
of Ago2 siRNA compared to control siRNA. Collectively, these studies indicate that changes in 
LC3B and cleaved PARP protein occurred via a miRNA-dependent mechanism.    
 
miR-494-mediated apoptotic induction occurs in the absence of change in protein levels of pro-
caspases or nuclear localization of AIF 
Apoptosis is a type of programmed cell death mechanism that primarily involves the 
activation of the caspase family of proteases [162]. However, caspase-independent apoptosis is 
also an established phenomena which is mediated by the movement of apoptosis-inducing 
factor (AIF) from the mitochondria into the nucleus [272]. We next investigated the mechanism 
of apoptotic cell death elicited following miR-494 transfection. Therefore, we transfected 769-P 
cells with miR-494 mimic along with the negative control mimic to determine the protein levels of 
both initiator (pro-caspase 2, 8, and 9) and executioner (pro-caspase 3) pro-caspases [273] via 
western blotting analyses. Since our group has previously shown that As2O3 induces a caspase-
dependent apoptotic cell death in normal ovarian T80 cells, we utilized this cell line treated with 
increasing doses of As2O3 as our positive control [15]. As shown in Figure 26A, we observed a 
decrease in pro-caspase 2, 3, 8, and 9 with increasing doses of As2O3 in T80 cells; however, 
this was not observed in miR-494 expressing 769-P cells. Furthermore, AIF did not nuclear 
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localize in miR-494 expressing cells, as determined by immunofluorescence staining of AIF 
(Figure 26B). These results indicate that apoptotic cell death elicited by miR-494 is not 
dependent on either the change in protein levels of caspases or the nuclear localization of AIF.  
 
 
 
 
 
Figure 26: Mechanism of miR-494-induced apoptosis 
 
(A) T80 cells were treated with 2, 5, 10, 25, and 50 µM As2O3 for 18 hours and protein lysates 
were collected. 769-P cells were transfected with control or miR-494 mimic and protein lysates 
were harvested 96 hours post-transfection. All the samples were run on a 10% SDS-PAGE gel 
and western blotting analysis was performed using the specified antibodies. The data shown is 
representative of two different experiments. (B) Control or miR-494 mimic transfected 769-P 
cells were re-seeded at 150,000 cells/well on glass coverslips. Cells were stained with AIF 
primary antibody overnight at 96 hours post-transfection and further stained with goat anti-
rabbit Alexa Fluor-546 secondary antibody. Coverslips were then mounted on slides using 
DAPI mounting media. Confocal imaging was performed and representative images from three 
different experiments are shown.   
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miR-494 reduces Bcl-2 protein levels and knockdown of Bcl-2 mimics effects elicited by miR-
494 expression 
Since we observed changes in LC3B protein levels with miR-494 expression and LC3B 
is an important autophagic marker, we next sought to identify putative miR-494 autophagy 
target genes. We initially performed an in silico analysis of autophagy-related genes listed in  
 
Figure 27: miR-494 reduces Bcl-2 protein levels 
 
(A) A diagram depicting the 3 imperfect miR-494 binding sites at the 3’UTR of Bcl-2 is shown. (B) 
769-P cells were transfected with negative control or miR-494 mimic and protein lysates were 
harvested 96 hours post-transfection. Samples were run on a 10% SDS-PAGE gel and western 
blotting analyses were performed using the specified antibodies. The data shown is 
representative of three different experiments. (C) 769-P cells were seeded at 750,000 cells/well. 
Following overnight adherence, cells were transfected with control or Bcl-2 siRNA. Twenty-four 
hours post the first round of transfection, cells were transfected again with the siRNA and protein 
lysates collected 48 hours post the second transfection. Samples were run on a 10% SDS-PAGE 
gel and western blotting analysis was performed using the specified antibodies. The data shown 
is representative of three different experiments.    
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the Human Autophagy Database (HAD) [185] using TargetScanHuman. One of the hits 
obtained from this analysis was Bcl-2, a negative regulator of both autophagy and apoptotic 
pathways [274]. The 3’UTR of Bcl-2 harbors three different imperfect miR-494 binding sites 
(Figure 27A). Since our western blot results demonstrated an increase in the protein levels of 
both autophagic and apoptotic markers (LC3B and cleaved PARP, respectively), we wondered 
whether Bcl-2 protein levels were altered upon miR-494 expression. As indicated in Figure 27B, 
there was a marked reduction in Bcl-2 protein levels upon miR-494 mimic transfection. Next, we 
assessed functional responses in 769-P cells upon knockdown of Bcl-2 via siRNA-mediated 
strategy. A similar increase in LC3B and cleaved PARP upon Bcl-2 siRNA was observed similar 
to miR-494 transfection (Figure 27C). We next attempted to investigate the effect of Bcl-2 
knockdown on the increase in LC3B and cleaved PARP observed in miR-494 expressing 769-P 
cells. For this purpose, we co-transfected 769-P cells with Bcl-2 siRNA and miR-494 mimic, 
followed by western blotting analyses for LC3B and cleaved PARP. Unfortunately, the western 
blotting data indicated an absence of changes in Bcl-2 protein levels in cells transfected with 
both control siRNA and miR-494 mimic (results not shown), which was in contrast to what was 
observed with miR-494 mimic transfection alone (Figure 27B). Therefore, since our prior 
observation that miR-494 mimic reduced Bcl-2 protein levels was not reproduced when the cells 
were also transfected with control siRNA in addition to miR-494, we could not interpret the 
results. Hence, these experimental problems that were encountered made it difficult to derive 
conclusive data on the combinatorial effect of Bcl-2 siRNA and miR-494 mimic expression in 
769-P cells. We next performed luciferase assay measurements to determine whether miR-494 
reduces the expression of Bcl-2. For this purpose, we transfected a normal cell line with a 
luciferase plasmid harboring the Bcl-2 3’UTR downstream of the firefly luciferase gene along 
with miR-494 mimic. The plasmid also harbored a renilla luciferase gene for determining 
transfection efficiency. No difference was observed in the relative luminescence values with 
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miR-494 mimic, compared to control (results not shown), suggesting that Bcl-2 may be an 
indirect target of miR-494. 
 
Investigation of miR-494 targets via RT2-PCR arrays identify LC3B as a potential target 
In our search for miR-494 targets, we next analyzed autophagy and apoptosis pathway 
focused RT2-PCR arrays to identify potential targets. These arrays identified an increase in 
LC3B with miR-494 expression (results not shown). We validated the increase in LC3B mRNA 
levels in miR-494-expressing cells by performing real-time PCR analysis using FAM-labelled 
TaqMan probes/primers and noted a fold increase of 1.39 (Figure 28A). Interestingly, LC3B was 
Figure 28: LC3B, a potential direct target of miR-494 
 
(A) Control or miR-494 mimic transfected 769-P cells were processed for miRNA isolation 96 
hours post-transfection. LC3B mRNA levels were quantified by real-time PCR using the 
correlative method and -actin was used as the endogenous control. RNA-fold changes are 
presented. The data shown is compiled from three different experiments. (B) A diagram 
depicting the 2 imperfect miR-494 binding sites at the 3’UTR of LC3B is shown. (C) T80 cells 
were transfected with pEZX-MT01 luciferase plasmid harboring LC3B 3’UTR downstream of 
the luciferase gene with control or miR-494 mimic. Cells were processed for luciferase assay 
and luminescence readings captured 24 hours post-transfection (as described in Chapter 2). 
The data shown is compiled from three different experiments.   
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also identified as one of the targets of miR-494 in the above mentioned in silico analysis (using 
HAD). A schematic representation of the miR-494 binding sites (2 imperfect sites) within the 
3’UTR of LC3B is shown in Figure 28B. Also, as indicated above, we observed an increase in 
LC3B protein levels with miR-494 expression (Figure 23B). Since there have been reports 
indicating that miRNAs can also up-regulate the expression of target genes [128-130] and 
induce translational up-regulation via direct binding at 3’UTR sites [275], we next assessed 
whether miR-494 binds to the 3’UTR of LC3B. For this purpose, we performed a luciferase 
assay, as described above for Bcl-2. As shown in Figure 28C, we observed a significant 
decrease in the relative light units with miR-494 expression, relative to control transfected cells, 
indicating that LC3B may be a potential target of miR-494. Additional studies involving 3’UTR 
mutations in the miR-494 binding site will need to be performed in order to confirm LC3B as a 
direct target of miR-494.    
  
Increase in LC3B mRNA and protein levels upon miR-494 transfection occur in the absence of 
autophagic flux changes 
Since elevated LC3B levels may suggest increased autophagic flux [276], we next 
wanted to identify changes in autophagic flux upon miR-494 expression. We initially assessed  
Figure 29: miR-494 expressing cells exhibit increased LC3B punctae without changes in 
autophagic flux (*Continued on next page) 
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Figure 29: miR-494 expressing cells exhibit increased LC3B punctae without changes in 
autophagic flux 
 
(A) Control or miR-494 mimic transfected 769-P cells were re-seeded at 150,000 cells/well on 
glass coverslips. Cells were stained with LC3B primary antibody overnight at 96 hours post-
transfection and further stained with goat anti-rabbit Alexa Fluor-546 secondary antibody. 
Coverslips were then mounted on slides using DAPI mounting media. Confocal imaging was 
performed and data shown is representative of two different experiments. (B) 769-P cells stably 
expressing mCherry-GFP-LC3B fusion protein were transfected with negative control or miR-494 
mimic. Protein lysates were harvested 96 hours post-transfection. Samples were run on a 10% 
SDS-PAGE gel and western blotting analysis was performed using the specified antibodies. The 
data shown is representative of three different experiments. (C) 769-P cells stably expressing 
mCherry-GFP-LC3B fusion protein were transfected with negative control or miR-494 mimic. 
Twenty-four hours post-transfection, cells were re-seeded at 150,000 cells/well on glass 
coverslips. Ninety-six hours post-transfection, coverslips were mounted on slides using DAPI 
mounting media. Confocal imaging analysis was performed and representative images are 
presented. The data shown is representative of three different experiments. (D) Confocal imaging 
data from (C) was quantified using the Image J macro analysis. Number of punctae and number of 
punctae area/cell for green, red, and merged punctae is presented.  
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endogenous LC3B staining in miR-494-transfected cells. As indicated in Figure 29A, an 
increase in both the number and intensity of LC3B punctae was observed in miR-494 
expressing cells, relative to control. In order to determine changes in autophagic flux, we 
performed immunofluorescence analysis, using the pH-sensor mCherry-GFP-LC3B fusion 
protein, developed by Hundeshagen and group [277]. The GFP-tag in this protein is acid-
sensitive and loses its green fluorescence when the autophagosome fuses with the lysosome, in 
contrast to the mCherry tag (red fluorescence) which is acid-insensitive [277]. This strategy 
distinguishes the lysosomes from the autophagosomes and hence determines autophagic 
turnover [277]. Therefore, we established retroviral stable 769-P cells overexpressing mCherry-
GFP-LC3B fusion protein and validated the protein levels via western blotting analysis in the 
absence or presence of miR-494 mimic transfection (Figure 29B). As shown in Figure 29C and 
29D, there was no change in autophagic flux with miR-494 expression, relative to control. We 
evaluated the data obtained from this analysis by confocal analysis and further quantified using 
Image J macro analysis program. However, both confocal imaging and quantitative analysis 
indicated an increase in punctae area, suggesting an increase in autophagosome size.  
 
miR-494 expression leads to accumulation of LDs, an event mediated via LC3B 
In order to examine cellular changes upon miR-494 expression, we performed TEM 
analysis in control and miR-494 expressing cells. Interestingly, we observed an increase in the 
number of LDs in miR-494 expressing cells (Figure 30A). Additionally, there was also an 
increase in cholesterol clefts and multilamellar bodies. We next performed staining of neutral 
lipids (using green LipidTOX stain) in cells transfected with negative control or miR-494 mimic in 
order to assess change in LDs size/number. Both the number and size of LDs increased 
significantly with miR-494 (Figure 30B and 30C).  
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Figure 30: Accumulation of LDs in miR-494 expressing cells occurs in an LC3B-
dependent mechanism (*Continued on next page) 
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Figure 30: Accumulation of lipid droplets in miR-494 expressing cells occurs in an 
LC3B-dependent mechanism (*Continued on next page) 
	
LDs in miR-494 expressing cell  occurs in an LC3B-
depen nt mechanism (*Continued on next page)
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Figure 30: Accumulation of LDs in miR-494 expressing cells occurs in an LC3B-
dependent mechanism (*Continued on next page) 
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Figure 30: Accumulation of LDs in miR-494 expressing cells occurs in an LC3B-
dependent mechanism (*Continued on next page) 
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We also measured total cholesterol content in 769-P cells transfected with control or miR-494 
mimic. Surprisingly, in contrast to the TEM results, we observed a decrease in cholesterol 
content with miR-494 (Figure 30D). This reduction in cholesterol levels was similar to the effect 
of certain chemotherapeutic agents that reduce intracellular cholesterol and sensitize cancer 
Figure 30: Accumulation of LDs in miR-494 expressing cells occurs in an LC3B-
dependent mechanism  
 
(A) Transmission electron micrographs of 769-P cells transfected with negative control or miR-
494 mimic. Green arrows indicate LDs, blue arrows indicate multilamellar bodies, and yellow 
arrows indicate cholesterol clefts. (B) Control or miR-494 mimic transfected 769-P cells were 
re-seed at 150,000 cells/well on glass coverslips. Ninety-six hours post-transfection cells were 
stained with green neutral lipid stain (LipidTOX). Coverslips were then mounted on slides using 
DAPI mounting media. Confocal imaging was performed and data shown is representative of 
three different experiments. (C) The data as shown in (B) was quantified and is presented in a 
graphical manner, compiled from three different experiments. (D) Protein lysates were collected 
from control or miR-494 mimic transfected 769-P cells and were then processed as described 
in Chapter 2 for cholesterol measurement. The data shown is compiled from three different 
experiments. (E) Protein lysates were collected from control transfected HK-2, 769-P, 786-O, 
and A-498 cells and were then processed as described in Chapter 2 for cholesterol 
measurement. The data shown is compiled from three different experiments. (F) 769-P cells 
transfected with control, LC3B, or ATG7 siRNA were re-seeded at 250,000 cells/well. Twenty-
four hours post re-seeding, cells were transfected with negative control or miR-494 mimic. 
Representative light microscopic pictures are presented from three different experiments. (G) 
Cells were processed as described in (F). Protein samples collected 96 hours post-transfection 
were run on a 10% SDS-PAGE gel and western blotting analyses were performed using the 
specified antibodies. The data shown is representative of three different experiments. (H) Cells 
were transfected as stated in (F). Ninety-six hours post-transfection, both adherent and floating 
cells were collected and processed, as indicated in Chapter 2. Cells were further stained with 
annexin V-FITC and PI followed by flow cytometry. Raw data plots (upper panel), and the 
percentage of viable, early apoptotic, and late apoptotic/necrotic cells are presented (bottom 
left panel). A table summarizing all the p-values is presented (bottom right panel). The data 
shown is compiled from three different experiments. (I) 769-P cells transfected with control, 
LC3B, or ATG7 siRNA were re-seeded at 250,000 cells/well on glass coverslips. Twenty-four 
hours post re-seeding cells were transfected with negative control or miR-494 mimic. Ninety-six 
hours post-transfection cells were stained with green neutral lipid stain (LipidTOX). Coverslips 
were then mounted on slides using DAPI mounting media. Confocal imaging was performed 
and representative images from three different experiments are shown. (J) Graphical 
representation of data as presented in (I). (K) A table showing p-values for the graph presented 
in (J). (L) A diagram depicting perfect miR-494 binding site at the 3’UTR of PRKAG2. (M) 
Control or miR-494 mimic transfected 769-P cells were processed for miRNA isolation 96 hours 
post-transfection. PRKAG2 mRNA levels were quantified by real-time PCR using the 
correlative method and -actin was used as the endogenous control. RNA-fold changes 
compiled from three different experiments are presented.  
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cells to cell death response [278]. Furthermore, we noted that the total cellular cholesterol levels 
were elevated in renal cancer cells compared to the normal immortalized HK-2 cells (Figure 
30E). Collectively, these results suggest that miR-494 expression can mediate metabolic 
changes which may contribute to the observed reduced cellular viability in 769-P renal cancer 
cells. We next investigated the mechanism of LD accumulation and thus used siRNA-mediated 
knockdown strategy against LC3B and ATG7 since both these proteins associate with outer LD 
membrane [279]. Additionally, depletion of ATG7 also induces LD accumulation in ATG7-/- 
mouse model [280]. Captured light micrographs (Figure 30F) showed that ATG7 knockdown 
markedly reduced cell numbers compared to control siRNA. The expression of miR-494 in 
ATG7 knockdown cells appeared to further decrease cell numbers. We next assessed changes 
in LC3B and cleaved PARP levels upon knockdown of LC3B and ATG7. As demonstrated in 
Figure 30G, we observed an altered ratio of LC3B-I/II with ATG7 siRNA. miR-494 expression 
led to an increase in cleaved PARP in control, LC3B, and ATG7 siRNA treated cells. However, 
annexin V/PI staining did not demonstrate a large change in apoptotic cell death in miR-494 
expressing cells with LC3B or ATG7 knockdown as compared to control siRNA (Figure 30H). 
These results indicate that the contribution of ATG7 and LC3B to the miR-494-mediated cell 
death response is negligible.     
LipidTOX staining indicated an increase in LDs with ATG7 siRNA, which further 
increased with miR-494 transfection (Figure 30I, 30J, and 30K). miR-494 transfection along with 
LC3B siRNA led to a significant reduction in LDs, as compared to control siRNA. These studies 
indicate that miR-494 mediated LD accumulation is LC3B-dependent and ATG7-independent. 
Next, in order to investigate whether miR-494 was involved in the regulation of genes 
associated with lipid metabolism, we performed another pathway focused RT2-PCR array for 
lipoprotein signaling and cholesterol metabolism. We identified an increase in the expression of 
the gamma subunit of AMPK (PRKAG2) (results not shown). PRKAG2 harbors a perfect miR-
494 binding site in its 3’UTR (Figure 30L). We validated the increase in PRKAG2 mRNA levels 
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in miR-494-expressing cells by performing real-time PCR analysis using FAM-labelled TaqMan 
probes and primers (Figure 30M). We also attempted to determine the protein changes in 
PRKAG2 upon miR-494 expression; however, the antibody failed to detect a band at the 
appropriate molecular weight (results not shown).   
 
Mitochondrial structural organization is altered upon miR-494 expression in 769-P cells 
The TEM analysis also demonstrated an increased number of electron dense regions in 
the mitochondria in cells expressing miR-494. These electron dense regions represent calcium 
accumulation which may indicate mitochondrial injury or degradation [281] (Figure 31A). In 
order to examine mitochondrial structural changes with miR-494, we performed 
immunofluorescence staining with cytochrome c, a mitochondrial protein marker which is 
located in the mitochondrial intermembrane space [282]. Additionally, we also co-stained for 
LC3B in order to assess their co-localization pattern. Not only did we observe an increase in 
LC3B punctae (as seen previously in Figure 29A), we also noted that the staining pattern of 
cytochrome c was disorganized in miR-494 expressing cells compared to control (Figure 30B). 
Data quantification was performed by grouping the images captured based on mitochondrial 
structural patterns into four categories (Figure 30C). These categories included (1) tubular, (2) 
tubular shortened, (3) tubular shortened fragmented, and (4) fragmented mitochondria. We 
observed a greater percentage of miR-494 expressing cells in the category 3 or 4 (tubular 
shortened fragmented or fragmented mitochondria).  
Mitochondria structural patterns are regulated by fission and fusion processes [283]. 
Proteins such as Parkin and PTEN-induced putative kinase 1 (PINK1) play critical roles in 
maintaining mitochondrial structural dynamics [284]. Dynamin-related protein 1 (Drp1) is 
another critical mitochondrial fragmentation associated protein [283]. In order to further our 
understanding of mitochondrial structural alterations, we next examined the protein levels of 
these mitochondrial proteins reported to be associated with mitochondrial fragmentation.  
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Figure 31: miR-494 induces disorganized structural mitochondrial patterns (*Continued 
on next page) 
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Figure 31: miR-494 induces disorganized structural mitochondrial patterns 
 
(A) TEMs of 769-P cells transfected with negative control or miR-494 mimic. Yellow arrows 
indicate electron dense regions in the mitochondria. (B) Control or miR-494 mimic transfected 
769-P cells were re-seeded at 150,000 cells/well on glass coverslips. Cells were stained with 
LC3B primary antibody overnight at 96 hours post-transfection and further stained with goat anti-
rabbit Alexa Fluor-546 secondary antibody. On the same day, cells were then stained with 
cytochrome c primary antibody overnight. The next day goat anti-mouse Alexa Fluor-488 was 
applied. Coverslips were then mounted on slides using DAPI mounting media. Confocal imaging 
was performed and data shown is representative of three different experiments. (C) 
Representative images captured via confocal microscope demonstrating the different 
mitochondrial structural patterns (as stated in the text). A table showing the number of cells 
assessed, the designated category, and punctae number is presented. (D) 769-P cells were 
transfected with negative control or miR-494 mimic and protein lysates were harvested 96 hours 
post-transfection. All the samples were run on a 10% SDS-PAGE gel and western blotting 
analyses were performed using the specified antibodies. The data shown is representative of 
three different experiments. (E) Control or miR-494 mimic transfected 769-P cells were re-
seeded at 150,000 cells/well on glass coverslips. Cells were stained with Drp1 primary antibody 
overnight at 96 hours post-transfection and further stained with goat anti-rabbit Alexa Fluor-546 
secondary antibody. On the same day, cells were then stained with cytochrome c primary 
antibody overnight. The next day goat anti-mouse Alexa Fluor-488 was applied. Coverslips were 
then mounted on slides using DAPI mounting media. Confocal imaging was performed and data 
shown is representative of three different experiments.  
	
	101 
	
As shown in the western blotting analyses in Figure 31D, we observed a decrease in 
PINK1 protein levels but no change in Drp1. Reduced PINK1 protein has been previously 
reported to contribute to mitochondrial fragmentation (mediated by Drp1) and oxidative stress- 
induced mitophagy [285, 286]. Therefore, we next examined subcellular localization of Drp1 via 
immunofluorescence analysis upon co-staining with both Drp1 and cytochrome c. As shown in 
Figure 31E, increased Drp1 co-localization with cytochrome c was observed in miR-494 
expressing cells. Further, we also assessed mitochondrial superoxide levels in miR-494 
expressing cells using the MitoSOX assay; however, no difference was observed results not 
shown). Collectively, these experimental outcomes may suggest that increased mitochondrial 
disorganization/fragmentation upon miR-494 transfection may be due to PINK1 loss and altered 
Drp1 localization. 
   
Discussion  
Clear cell renal carcinoma is the most common form of kidney cancer and is 
characterized by the loss of the VHL tumor suppressor gene, located at 3p25 [287]. The loss of 
this region is related to increased risk of renal cancer and poor patient outcome [23, 287, 288]. 
The additional loss of chromosome 14q along with 3p deletions leads to increased 
aggressiveness of this cancer [23]. miRNAs are frequently found in such genomic regions; 
indeed, the 14q region harbors one of the largest miRNA clusters in the human genome [119]. 
The role of these miRNAs in cancer biology is unclear. miRNAs regulate key cellular processes 
and many are associated with reduced cellular growth. miR-494 in other cancer cell types has 
also been shown to be associated with reduced cell viability [138, 248, 289], although a detailed 
mechanism has yet to be elucidated. In this chapter, we show that miR-494 leads to reduction in 
cell growth in normal and renal cancer cells. miR-494 failed to elicit these effects in the 
presence of Ago2 siRNA or transfection with anti-miR-494 leading to a reversal in miR-494-
mediated changes, indicating that our experimental outcomes were miRNA-dependent. As 
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demonstrated in Figure 32, miR-494 increased LC3B mRNA and protein levels. LC3B may be a 
potential miR-494 target as indicated by the luciferase assay and miRNAs have been reported 
to enhance target gene expression [128-130]. miR-494 expression also led to increased cleaved 
PARP and apoptosis. miR-494 expressing cells exhibited increased LC3B punctae and 
mitochondrial disorganization. The accumulation of LDs in miR-494 expressing cells was 
mediated by LC3B. Small LDs that increased with the knockdown of ATG7 occurred 
independently of miR-494.   
Figure 32: Schematic of miR-494 functional responses in 769-P renal cancer cells 
 
miR-494 expression leads to accumulation of LDs, which is mediated by LC3B; however, ATG7 
induces small LDs formation, independently of miR-494. miR-494 expression also leads to 
reduced cholesterol levels and increased mitochondrial structural disorganization. These cellular 
changes are accompanied by reduced growth and increase in cell death. (*Figure created by 
Punashi Dutta) 
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In order to delineate the cell death mechanism mediated by miR-494, we investigated 
mitochondrial changes since these are critical in the intrinsic apoptotic pathway. However, we 
did not witness any change in pro-caspase levels via western analysis or the movement of AIF 
to the nucleus, an event which occurs in caspase-independent cell death.  Cell death upon miR-
494 expression occurred with a reduction in PINK1 protein levels (a kinase involved in 
mitochondrial fission/fusion effects) and altered subcellular localization of Drp1 (a protein 
associated with mitochondrial fission). The loss of PINK1 has been previously reported to 
enhance Drp1 recruitment to mitochondria and induce mitochondrial fission, along with increase 
in oxidative stress and mitophagy [285, 286]. Although, the mitochondrial superoxide levels 
were found to be unaltered in miR-494 expressing cells, we observed increased LC3B punctae, 
associated with disorganized mitochondria. 
Kidney cancer exhibits metabolic dysfunction including increase in LDs which are 
composed of triglycerides and cholesterol esters [290]. These LDs have also been found to be 
increased upon chemotherapeutic treatments such as with simvastatin [291]. Simvastatin is a 
chemotherapeutic drug that induces apoptosis and there have been reports showing that 
apoptosis is accompanied by mitochondrial loss of function and increased LD formation [292]. 
Interestingly, from our studies shown in Figure 30, we noted an increased accumulation of LDs, 
which was associated with reduced cell survival and increase in late apoptotic cell numbers. 
Along with changes in cleaved PARP levels and cell death, miR-494 also increased LC3B levels 
(mRNA and protein). Indeed, as shown in Figure 29A, we saw an increase in endogenous LC3B 
levels in the parental 769-P cells upon miR-494 expression in the absence of change in 
autophagic flux. Autophagy is involved in the turnover of lipids, a process referred to as 
lipophagy [293] and autophagic proteins have major roles in LD biogenesis [279]. Previous 
studies have demonstrated both ATG7 and LC3B to be associated with LDs [279]. ATG7 is 
critical in the conjugation of LC3-I to LC3-II; however, since the formation of LDs can occur in an 
ATG7–independent mechanism since LC3B is known to be localized to LDs both in its 
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conjugated and non-conjugated form. Therefore, ATG7 is dispensable for this event [294], as 
also observed in our studies (Figure 30). Consistent with our observation regarding the increase 
in small LDs with ATG7 siRNA, ATG7 knockout mouse model has also been reported to lead to 
increased LDs [280]. LDs are dynamic organelles and it has been previously reported that the 
presence of certain proteins at the LD-LD contact site can mediate LD growth by directional 
transfer of lipids from a smaller to a larger LD [295]. Our findings as reported in this chapter 
show an increase in LDs upon miR-494 expression, a process that is LC3B dependent and is 
associated with reduced renal cancer cell survival.       
Furthermore, AMPK mediates lipid synthesis by decreasing malonyl-CoA [296] and we 
observed a significant increase in PRKAG2 (gamma subunit of AMPK) mRNA levels upon miR-
494 expression. The increase in LC3B and PRKAG2 upon miR-494 expression implicates the 
role of miRNAs in positively regulating gene expression, as also reported in other studies [128, 
129]. Although we noted the presence of cholesterol clefts in miR-494 expressing cells via 
TEMs, similar in nature to that reported for arthrosclerosis [297]; miR-494 expressing cells 
exhibited reduced total cellular cholesterol levels. Indeed, the cholesterol disrupting agents such 
as lovastatin can lead to improved sensitivity to chemotherapeutic agents [278, 298, 299] in 
cancer cell lines. Our observation that cholesterol levels were increased in our renal cancer cell 
lines supports this notion that increased cholesterol levels can confer resistance to 
chemotherapeutic agents and in the present study towards miR-494.   
Certain miRNAs have been known to regulate lipid metabolism, via targeting important 
genes in the pathway. these include miR-33, miR-122, miR-378 and miR-125 [300]. miR-33 is 
located in the intronic region of SREBF-2, a critical regulator of genes involved in cholesterol 
synthesis [300]. Of interest, certain miRNAs at the 14q locus have also been reported to 
regulate lipid biogenesis. These include miR-370 [300], miR-376a [301], miR-379 [302] and 
miR-410 [303]. We propose that miR-494 may be involved in modulating the expression of 
genes involved in lipid biogenesis altering the turnover of lipids and thus leading to their 
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accumulation. It will be worthwhile to assess the combinatorial effect of miRNAs at 14q32 locus, 
in mediating cell death in renal cancers.  
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Chapter 6  
 
Future Directions and Significance of the Study 
 
Overview of the Major Findings   
Genomic alterations contribute to the development of cancers [11]. Therefore, 
characterizing specific genes located within these altered chromosomal regions and their 
associated functions are important in understanding cancer biology. This dissertation focuses 
on the contribution of specific genes located at the 3q26.2 [1, 2] (EVI1 and SnoN) and 14q32 
[23] (miR-494) loci to ovarian and renal cancer pathophysiology, respectively. As presented in 
Chapter 3, we demonstrated that the knockdown of EVI1 splice variants altered the mRNA and 
protein levels of certain EMT markers in ovarian and breast cancer cells [14]. We also showed 
that the migratory potential of these cells was altered upon knockdown of specific EVI1 splice 
forms.  When we measured the expression of miR-200 a/b/c (critical regulators of EMT), we 
identified that their levels were unchanged in the siME (reduces the expression of MDS1/EVI1 
and EVI1Del190-515) knockdown cells relative to control siRNA treated cells [14]. When we 
overexpressed specific EVI1 splice forms, we noted changes in Cyclin E1 expression [14]. In 
Chapter 4, we focused on another gene located within the 3q26.2 region, SnoN/SkiL. We 
previously reported that the EGFR and PI3K/AKT pathway contributes to induction of SnoN/SkiL 
upon drug treatment [17]. In this dissertation, we assessed the contribution of miRNAs in the 
regulation of SnoN expression upon As2O3 treatment in HEY ovarian cancer cells. We 
performed in silico analysis using several bioinformatics programs and identified a subset of 
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miRNAs (including miR-494) that could potentially bind to the 3’UTR of SnoN. We also identified 
that miR-494 sensitized HEY cells to As2O3 treatment.  
Kroeger and colleagues identified that loss of 14q chromosomal region (which harbors 
54 miRNAs) correlates with a worsened patient outcome in clear cell renal carcinoma [23]; 
however, the method which was employed (cytogenetic analyses) would not be able to 
determine the exact bases deleted in this region. There are other methods that will allow one to 
delineate the exact locus deleted giving a clear picture of which genes are altered. However, 
there are reports that alterations at the 14q32 locus are associated with disease pathogenesis 
[253, 304]. In Chapter 5, we specifically focused on the contribution of miR-494 (one of the 
miRNAs located within this cluster) in renal cancer pathophysiology. Several of the so far 
identified miR-494 targets are associated with reduced cell survival [26, 136-138, 248, 249, 
252]; however, the role of miR-494 in renal cancer is presently unknown. In our TCGA analysis, 
we determined that the expression of miR-494 was reduced in kidney renal clear cell carcinoma 
(KIRC) samples relative to control specimens (data not shown). We demonstrated that 
expression of miR-494 in 769-P renal cancer cells reduced cellular viability by partially inducing 
apoptosis which occurred in a caspase- and AIF-independent manner. We also delineated the 
involvement of specific autophagic mediators, such as LC3B and ATG7, in miR-494 mediated 
responses. miR-494 increased both LC3B mRNA and protein levels. Additionally, miR-494 
expression altered the structure of the mitochondria and also induced the formation of LDs. The 
increase in LDs upon miR-494 expression was mediated by LC3B, which could potentially be a 
direct target of miR-494 (assessed via a luciferase-based assay whereby co-transfection of 
control or miR-494 mimic was performed with a plasmid harboring the 3’UTR of LC3B 
downstream of the luciferase gene).  
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Chapters 3 and 4: Limitations of the Studies 
In Chapter 3 involving overexpression or knockdown studies of EVI1 splice variants, we 
acknowledge challenges in data interpretation.  Each cell line (with the exception of OVCAR8 
cells which contains a deletion at the 3q26.2 locus as determined by aCGH [2]) has a certain 
baseline expression of specific EVI1 splice variants. By altering expression of one form via 
overexpression, the ratios of the endogenous specific splice forms are thus altered. Also, since 
the knockdown is not specific to one splice variant, it is difficult to attribute the altered functional 
effects to a specific splice variant. For example, siME reduces both MDS1/EVI1 and the 
EVI1Del190-515 forms; however, this leads to an increase in the wild type EVI1 form relative to the 
other splice forms.  
In Chapter 4, we identified that miR-494 could sensitize HEY ovarian cancer cells and 
modulate SnoN/SkiL expression in the presence of As2O3 treatment. As2O3 is used in 
hematological malignancies as an important chemotherapeutic agent that has been FDA-
approved [221]. However, there is little success in its use as a chemotherapeutic agent in solid 
cancers due to the increased dosage which may lead to toxic effects [305]. Nevertheless, the 
mechanism underlying SnoN induction upon treatment with drugs is of importance because 
platinum-based drugs such as cisplatin also induce SnoN (results not shown). This mechanism 
of SnoN up-regulation needs to be further investigated. 
 
Chapter 5: Potential Mechanisms Underlying Altered Mitochondrial Organization and 
Accumulation of LDs with miR-494 Expression  
 
miR-494 expression increases LC3B levels: implications in lipid metabolism 
LDs are cellular organelles composed of triacylglycerol and cholesterol esters, primarily 
involved in the storage of lipids [306]. As presented in Figure 30 and 29, we observed an 
increase in LDs and LC3B punctae size in miR-494 expressing cells in the absence of changes 
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in autophagic flux. Since LC3B localizes to LDs [279], we attempted to determine whether LC3B 
also localized to LDs under our experimental conditions (i.e. miR-494 expression in 769-P cells). 
To address this question, we performed co-staining using the LC3B antibody with a neutral lipid 
dye (LipidTOX). Using our LC3B antibody (rabbit polyclonal) which requires methanol fixation 
followed by LipidTOX staining, our results indicated that methanol fixation alters lipid structure 
as previously reported [307]. Indeed, the use of -200C temperature-methanol or acetone fixation 
removes phospholipids from the LD membrane and promotes fusion of LDs [307]. 
Formaldehyde is the suggested fixation method which preserves the structure of the LDs [307]. 
Therefore, it was not technically possible to address our experimental question with the 
presently available tools. We suggest that an antibody against LC3B which requires 
formaldehyde fixation (which presently does not exist) would allow co-staining with LipidTOX. 
The outcome of this experiment once tools become available may indicate that LC3B may 
localize to both the LD membrane and the autophagosomal membrane, following miR-494 
expression. This is schematically depicted in Figure 33; we hypothesize that LC3B localizes to 
Figure 33: miR-494 leads to increased LC3B levels - implications in lipid metabolism 
 
miR-494 expression increases LC3B punctae accompanied with an increase in LC3B protein 
and mRNA levels. We propose that these LC3B punctae may associate with LD membranes or 
the autophagosome membranes engulfing LDs, or both. (*Figure created by Punashi Dutta) 
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LDs and/or to the autophagosome membrane, leading to the engulfment and clearance of LDs 
via autophagy (lipophagy) [293]. We propose that this could be assessed by TEM using 
immunogold-labelled LC3B antibody. The outcome of this study would provide information with 
regard to the co-localization of LC3B with LDs and/or autophagosomes. This information will 
would be important to connect our observations between LC3B levels, autophagosome size, 
and LD numbers in miR-494 expressing cells.  
 
Contribution of miR-494 in lipid metabolism 
It is well known that both saturated and unsaturated fatty acids such as palmitate (16:0) 
and oleate (18:1cis∆9) alter autophagic responses [308]. In Chapter 5, we demonstrate that 
miR-494 increases LD numbers, (which store fatty acids in the form of triacylglycerol) [306] and 
LC3B levels (an important mediator of autophagy) [309]. To determine whether miR-494 
expression alters the levels of saturated/unsaturated fatty acids which may in turn modulate 
autophagic and/or other cellular responses, we propose that one could assess the fatty acid 
(and other lipid) profile in miR-494 expressing cells. To address this question, one could perform 
lipidomic [310] studies involving GC-MS (Gas Chromatography-Mass Spectrometry). In order to 
identify miR-494 targets in the lipid metabolism pathway [311], we performed in silico analysis 
using TargetScan; we identified a subset of genes that harbored miR-494 binding sites (Table 
6). One such potential target included PPAP2C (phosphatidic acid phosphatase type 2C), which 
is involved in de novo synthesis of phospholipids and glycerolipids [312]. Its family member, 
PPAP2A, has been reported to be significantly up-regulated upon simvastatin treatment, a 
cholesterol depleting agent, which leads to the formation of LDs coincident with an apoptotic 
response [291]. In this regard, we propose that studies could be performed to investigate 
whether PPAP2C is altered upon treatment with miR-494 but also cholesterol depleting drugs. 
We also performed RT2-PCR pathway focused array for genes involved in lipoprotein signaling 
as well as cholesterol metabolism and found that the gamma catalytic subunit of AMPK 
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(PRKAG2) was significantly up-regulated upon miR-494 expression (results not shown). AMPK 
mediates lipid synthesis by decreasing malonyl-CoA levels; it is an enzyme that maintains 
balance between fatty acid -oxidation and lipogenesis [296]. Regrettably, we could not validate 
changes in its protein levels upon miR-494 expression. In order to further identify miR-494 
targets which may promote accumulation of LDs, we propose that other pathway focused RT2-
PCR arrays such as the fatty acid metabolism array could be employed. Dysregulated 
cholesterol biosynthesis is implicated in clear cell renal carcinoma [313]. Indeed, cholesterol 
levels in cells expressing miR-494 were reduced. One drawback of the amplex red cholesterol 
assay that we employed to measure cholesterol content is that it measures total cell cholesterol 
content instead of that specific to LDs which contains triacylglycerol and cholesterol esters 
[306]. Therefore, to measure triacylglycerol and cholesterol esters amounts specifically 
associated with the LD core, we would need to purify the LD enriched fraction from control and 
miR-494 expressing cells and then measure cholesterol levels.  
 
Involvement of miR-494 in mitochondrial dynamics and mitophagy 
Mitochondria are dynamic organelles that are constantly undergoing fission and fusion 
events [314]. Specific proteins have been so far identified to be involved in these important 
processes. The PINK1/Parkin pathway is essential in the maintenance of mitochondrial integrity 
[315] and the loss of PINK1 inhibits Drp1-dependent mitochondrial fission, promoting mitophagy 
(an autophagic process which clears damaged mitochondria) [286] [285]. In addition, autophagy 
proteins, ATG7 and LC3B, are involved in mitochondrial fragmentation [285]. As reported in 
Chapter 5, we observed distinct changes (either protein levels/intracellular 
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Table 6: A summary of a subset of genes involved in lipid metabolism harboring miR-
494 binding sites	
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localization) in several of these above-described proteins, involved in mediating mitochondrial 
changes. Indeed, in miR-494 expressing cells, we observed reduced PINK1 protein, increased 
LC3B mRNA and protein, and altered subcellular localization of Drp1. We propose that it would 
be important to understand how miR-494 modulates changes in these key proteins to better 
understand the contribution of miR-494 in altering mitochondrial dynamics and the mitophagy 
pathway. Although we identified LC3B as a target of miR-494 (through a 3’-UTR luciferase-
based assay), it is likely that the other proteins (Drp1 , Parkin, and PINK1) are regulated in an 
indirect manner since there were no miR-494 binding sites in the 3’UTR of PINK1, Parkin, or 
Drp1 via TargetScan. We propose that miR-494 may modulate expression of an upstream gene 
in the mitochondrial/mitophagy pathway which would indirectly affect PINK1 and Drp1. For 
example, NFB signaling has been reported to induce PINK1 expression [316]; although  miR-
494 induces expression of inflammatory cytokines in an NF-B-dependent manner, it has yet to 
be shown whether miR-494 modulates upstream signaling leading to activation of NF-B [317]. 
PINK1 recently is reported to regulate cell cycle progression and promote cell survival [318]; 
thus, it would be worthwhile to determine whether miR-494 alters cell cycle progression since 
we observed reduced PINK1 levels which is accompanied by reduced cellular growth. 
 
Accumulation of LDs in miR-494 expressing cells: mitochondrial involvement 
During starvation, cytoplasmic lipases hydrolyzes LDs to glycerol (which is converted to 
glucose by the liver) and fatty acids [319]. These fatty acids are substrates for-oxidation 
leading to the formation of acetyl CoA, which is used in the Krebs cycle; these steps  occur in 
the mitochondrial compartment [319]. Evidence implicates mitochondrial dysfunction or 
induction of apoptosis leads to inhibition of mitochondrial -oxidation resulting in re-direction of 
the fatty acids to LDs which then accumulate [292] [320] [321] [322]. Recent studies by 
Rambold and colleagues implicate both the autophagy and lipolysis pathways in the  trafficking 
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of fatty acids in starved cells [320]. Further, inhibition of mitochondrial fusion redirected fatty 
acids back to the LDs [320]. Indeed, in Chapter 5, we demonstrated that miR-494 increased 
LDs, accompanied by mitochondrial structural disorganization, reduced cell survival, and 
increased apoptotic cells. In order to determine whether miR-494 alters the rate of -oxidation, 
we propose to measure mitochondrial oxygen consumption rate (mtOCR) in miR-494 
expressing cells. 
Since we observed accumulation of fragmented mitochondria, we propose that miR-494 
may modulate targets that are involved in mitochondrial fusion (which is needed for transfer of 
fatty acids from LDs to mitochondria). Indeed, the 3’-UTR of mitofusin-1 (Mfn1) and mitofusin-2 
(Mfn2) (major proteins involved in mitochondrial fusion [323]) contain miR-494 binding sites.  
 
As depicted in Figure 34, there are perfect miR-494 binding sites in the 3’UTR of both 
Mfn1 and Mfn2. We hypothesize that miR-494 could modulate mitochondrial fusion by directly 
regulating the gene expression of Mfn1 and Mfn2. Since we observed increased Drp1 
localization to mitochondria in miR-494 expressing cells (suggestive of increased mitochondrial 
fission), we propose that miR-494 expressing cells have reduced rates of mitochondrial fusion 
Figure 34: Mfn1/Mfn2 - potential targets of miR-494  
 
Schematic showing the perfect complementarity of miR-494 binding sites within the 3’UTRs of 
Mfn1 and Mfn2. (*Figure created by Punashi Dutta) 
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which may then lead to increased numbers of fragmented mitochondria. Increased 
mitochondrial fragmentation is associated with increased apoptosis [324] [325-327] and/or 
mitophagy [285]. Figure 35 depicts a proposed model for the miR-494-mediated mitochondrial 
dynamic changes. 
Increase in reactive oxygen species are major causes of oxidative stress-induced 
mitochondrial dysfunction and damage [328]. Although we did not observe any changes in 
mitochondrial superoxide levels in miR-494 expressing cells compared to control cells, there 
may be changes in other reactive oxygen species (ROS) such as hydrogen peroxide and 
hydroxyl radical [329],  which may be worthwhile investigating. 
Figure 35: Potential contribution of miR-494 to the mitochondrial fission/fusion events 
  
We propose that miR-494 expression induces the localization of Drp1 to mitochondrial fission 
sites, leading to mitochondrial fragmentation, mitophagy, and apoptosis. Additionally, we 
propose that miR-494 targets Mfn1/2 and thus inhibits mitochondrial fusion, leading to 
apoptosis. (*Figure created by Punashi Dutta) 
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Cross-talk between miR-494 and the pro-survival Bcl-2 molecule 
Although we observed a reduction in Bcl-2 protein levels in miR-494 expressing cells via 
western blotting analyses (Chapter 5), 3’-UTR luciferase assays failed to demonstrate Bcl-2 as 
a direct target of miR-494. However, this suggests an inverse association between Bcl-2 and 
miR-494. Interestingly, Bcl-2 opposes BNIP1–mediated Drp1 recruitment to mitochondrial 
fission sites [330] (Figure 36A). Since we observed reduced Bcl-2 protein and increased 
recruitment of Drp1 to mitochondria in miR-494 expressing cells, we hypothesize that the 
presence of Bcl-2 may antagonize Drp-1 recruitment to mitochondrial fission sites; this would 
lead to increased mitochondrial fusion.  
Figure 36: Potential cross-talk between Bcl-2 and miR-494  
 
(A) Schematic of our proposed hypothesis whereby miR-494 reduces Bcl-2 protein which is 
reported to inhibit Drp-1 mediated mitochondrial fission. The cumulative effect of this pathway 
would then lead to increase mitochondrial fission in miR-494 expressing cells via Drp1. (*Figure 
created by Punashi Dutta). (B) Parental 769-P cells stably expressing pBABE-puro-Bcl-2 or 
mCherry-GFP-LC3B 769-P cells stably expressing pQCXIN-Bcl-2 were seeded at 250,000 
cells/well. Protein lysates were harvested 48 hours post-seeding. Samples were run on a 10% 
SDS-PAGE gel and western blotting analyses were performed using the specified antibodies. 
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We have begun to address this hypothesis by generating Bcl-2 overexpressing 769-P parental 
and mCherry-GFP-LC3B stable cell lines (Figure 36B). We propose to perform rescue 
experiments by expressing miR-494 in these Bcl-2 overexpressing stable cell lines; we would 
then assess changes in LD formation, Drp1 recruitment to mitochondria, modulation of 
autophagosome size, and cell death responses. If the reduction in Bcl-2 levels is required for 
the observed miR-494 cellular changes, we expect that Bcl-2 would antagonize the cellular 
responses mediated by miR-494. 
 
 
 
Figure 37: Overall model of proposed cellular effects mediating the cell death response 
elicited by miR-494 (*Continued on next page) 
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A schematic of our model depicting all the key proteins involved in miR-494-mediated 
responses is shown in Figure 37. We propose that miR-494 increases LC3B mRNA and protein 
levels, leading to increased co-localization of LC3B to LDs. miR-494 also reduces Bcl-2 and 
PINK1 protein levels and both these proteins antagonize the movement of Drp1 to mitochondrial 
fission sites, which inhibit mitochondrial fragmentation and mitophagy [285, 286, 330]. Since we 
identified miR-494 perfect match binding sites in the 3’UTR of both Mitofusin-1/2 via an in silico 
approach, a reduction in mitofusin expression may thus lead to increased Drp1 localization to 
mitochondria. This would next lead to fragmented mitochondria which would be deficient in -
oxidation, causing an efflux of fatty acids from mitochondria to the LDs which would 
subsequently lead to an over-accumulation of LDs and thus, cell death. 
 
Contribution of the miRNA Cluster at 14q32 in Renal Cancer Pathophysiology 
A study conducted by Laddha and colleagues analyzed the expression of the 14q32 
genomic cluster miRNAs across various cancers and found 61% of these to be down-regulated 
in renal cancer [304]. Several miRNAs at 14q32 regulate autophagic mediators. These include 
miR-379 which targets LAMP-2A [331], miR-376a and miR-376b which target ATG4C and 
beclin-1 [332, 333], and miR-410 which targets AMPK[334]. Additionally, several other 
miRNAs at 14q32 regulate genes in the lipid biosynthesis pathway including miR-370 [300], 
miR-376a [301], miR-379 [302], and miR-410 [303]. However, the detailed role of this miRNA 
Figure 37: Overall model of proposed cellular effects mediating the cell death response 
elicited by miR-494 
 
The model as presented summarizes our findings and links these to published reports in order 
to better understand the potential effects of miR-494 in lipid metabolism and mitochondrial 
dynamics. We propose that miR-494 targets Bcl-2, PINK-1, and Mfn1/2 thus increasing Drp-1 
mediated mitochondrial fission. We have shown herein, that miR-494 increases LC3B 
expression. We propose that LC3B localizes to LDs. Collectively, these effects lead to inhibition 
of mitochondrial fusion, transfer of fatty acids back to the mitochondria, reduction in -oxidation, 
and reduced cellular survival. (*Figure created by Punashi Dutta) 
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cluster in renal cancer biology is presently unclear. Therefore, it would be worthwhile to 
investigate the contribution of the other miRNAs present at the 14q32 locus in autophagy and/or 
altered lipid metabolism. 
A custom-design screen using a 96-well plate format in which each well contain a 
miRNA mimic (54 wells in total) could be designed for this purpose. By reverse transfection in 
parental 769-P cells, the formation of LDs would be assessed using LipidTOX green neutral lipid 
stain. This would be analyzed either manually or using an INCell Analyzer, if available. In a 
similar procedure, 769-P renal cancer cells stably overexpressing mCherry-GFP-LC3 would 
allow assessment of red/green punctae to identify changes in autophagic flux and 
autophagosome size. Additionally, a MTT survival assay using the above custom-designed 
screen and parental 769-P renal cancer cells could be performed to assess changes in cell 
viability. The positive hits that are identified via this screening strategy would then be assessed 
in in vitro experiments (using mimic and/or antagomirs). Since genes harboring neighboring loci 
on the chromosome may co-operatively regulate common cellular processes [335], we 
speculate that expression of a combination of a subset of these miRNAs in renal cancer cells 
may induce robust cellular changes including cell growth and viability. 
 
Renal Cancer Specimens: Cellular Changes with Altered miR-494 Expression 
TCGA analysis demonstrated that miR-494 levels were reduced by 32% in KIRC 
samples compared to normal (results not shown). To follow-up on this observation, we propose 
to assess changes in patient survival and chemotherapeutic responsiveness in panel of normal 
and renal cancer patient specimens with high/low expression of miR-494. It would also be 
worthwhile to assess fatty acid/phospholipid levels and mitochondrial dynamics across different 
stages of renal cancers. Additionally, using a real-time PCR and western analysis approaches, 
changes in mRNA and protein of autophagy markers in KIRC samples (compared to normal) 
across different stages of kidney cancer could be assessed. From kidney tumor specimens, 
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miR-494 levels and Bcl-2, PINK1, LC3B, Mfn1/2 mRNA, and protein levels can be assessed. 
Immunohistochemical analysis of cytochrome c, Drp1, and LC3B could be performed on the 
tissue specimens. Additionally, lipidomic studies and fatty acid measurements could also be 
performed on these specimens. The resultant data could also then be correlated to patient 
clinical variables.  
 
Renal Cancer Mouse Models: Effects of miR-494 on Tumor Growth 
To determine whether miR-494 alters in vivo tumor growth, we propose two different 
orthotropic cancer xenograft mouse studies as shown in Figure 7. For the purpose of the first 
study, stable cell lines overexpressing control (vector backbone) or miR-494 would be 
established. These cells will then be injected under the kidney capsule directly into the proximal 
kidney tubule of athymic nude mice, as shown in Figure 38. After the tumors are established, 
they would be excised from the mice and assessed for size/volume and histological features. 
Immunohistochemical analyses of the tumor sections will be performed to assess morphological 
changes including dysfunctional mitochondria and accumulation of LDs. TEM analysis will allow 
us to determine whether there is an alterations in LD formation. Using these specimens, we will 
also measure changes in mitochondrial -oxidation.    
In the second study, we will establish the tumor by subcutaneously injecting cancer cells 
into the athymic nude mice (Figure 38). After the establishment of the tumor, we would inject 
miR-494 mimic via an intratumoral injection into the mice. In order for the miRNA gene delivery 
strategies to be successful, it is of importance that certain hurdles such as their instability in 
vivo, inappropriate distribution, or off-target effects are overcome [336]. A recent study has 
suggested that the use of lipid-based vesicles, Stable Nucleic Acid Lipid Particles (SNALPs), as 
a tool for encapsulated delivery of miRNA mimic for in vivo studies may ease the miRNA mimic  
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delivery [337]. This strategy for miRNA mimic delivery could be utilized for the above study. 
Similar analytical strategy will be employed as described in the first study.      
As mentioned earlier, depletion of cholesterol activates the apoptotic response in cells; 
certainly, inhibitors that block cholesterol biosynthesis can induce apoptosis [278, 298, 299]. 
HMG CoA-reductase (an important enzyme involved in cholesterol biosynthesis) inhibitors such 
Figure 38: Proposed experimental outline to investigate the effects of miR-494 on tumor 
growth in mouse model 
 
Two different mouse models are proposed in the figure. In the first mouse study, miR-494 
expressing retroviral stable cell lines would be established and then injected into the proximal 
kidney tubule of an athymic nude mouse. After establishment and excision of the tumor 
following appropriate time period, analyses would be performed as indicated. In the second 
mouse study, cancer cells would be injected subcutaneously into the mice. After the 
establishment of the tumor, miR-494 mimic would be injected intratumorally into the mice 
using SNALPs. This study would be performed with or without the use of cholesterol depleting 
agents. Further analyses would be performed as indicated in the figure. (*Figure created by 
Punashi Dutta)  
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as lovastatin and simvastatin reduce cholesterol levels and induce apoptosis [338] [291]. Since 
renal cancer is a metabolic disease [41] with altered lipid metabolism, and cholesterol 
accumulation plays an important role in the disease progression [313], it would also be 
worthwhile to analyze the effect of these drugs along with miR-494 mimic in renal cancer cells to 
determine whether the addition of mimic can further strengthen the cell death response. Once 
we gain more insight into the outcome of this combinatorial regime in in vitro studies, these 
studies could then be applied in vivo, using a kidney cancer xenograft mouse model, as 
described above.  
Since miR-494 has not yet been studied in terms of organismal development, there is no 
information regarding whether this non-coding RNA is essential for survival or development of 
mice. There has not been any report as yet involving study with a miR-494 transgenic or 
knockout mouse model. It is presently unknown if such mice would be embryonically lethal or 
not. Therefore, we would generate a miR-494 whole-body transgenic and knockout mouse 
model and if these mice fail to live, we would then generate a tissue-specific mouse model for 
the kidney by using the kidney proximal tubule-specific type 1 -glutamyltranspeptidase 
promoter to drive the overexpression/knockdown [339]. The miR-494 knockout mouse model 
can be crossed with the PIK3CA mutant mouse (which has increased propensity to develop 
cancer); such mice will then be injected with adenoviral CRE recombinase harboring PIK3CA 
mutation [340] (renal cancer exhibit mutations at the 3q region [43]) and the tumor progression 
will be assessed. 
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